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Abstract Accumulating evidence suggests that serotonin may modulate cholinergic function in several 
regions of the mammalian brain and that these serotonergic/cholinergic interactions influence cognition. 
The first part of this review is an overview of histological, electrophysiological and pharmacological 
(in vitro, in vivo) data indicating that, in several brain regions (e.g., hippocampus, cortex and striatum), 
there are neuroanatomical substrates for a serotonergic/cholinergic interaction, and that alterations in 
serotonergic activity may induce functional changes in cholinergic neurons. In the second part, the review 
focuses on experimental pproaches showing or suggesting that central cholinergic and serotonergic 
mechanisms are cooperating/interacting in the regulation of cognitive functions. These arguments are 
based on lesion, intracerebral grafting and pharmacological techniques. 
It is concluded that not all mnesic perturbations induced by concurrent manipulations of the 
serotonergic and cholinergic systems can be attributed to a serotonergic modification of the cholinergic 
system. The cognitive faculties of an organism arise from interactions among several neurotransmitter 
systems within brain structures uch as, for instance, the hippocampus or the cortex, but also from 
influences on memory of other general functions that may involve cerebral substrates different from those 
classically related to mnesic functions (e.g., attention, arousal, sensory accuracy, etc.). 
Key words: cortex, hippocampus, 5-hydroxytryptamine, memory, pharmacology, striatum. 
*To whom correspondence should be addressed. 
Abbreviations: ACHE, acetytcholinesterase; AD, Alzheimer's disease; AF64A, ethylcholine aziridinium; AMPA, ~-amino-3- 
hydroxy-5-methyl-isoxazole propionate; BIMU 1, endo-N-(8-methyl-8-azabicyclo[3.2.1.]-oct-3-yl)-2,3-dihydro-3-ethyl- 
2-oxo-lH-benzimidazol-l-carboxamide; BIMU 8, endo-N-(8-methyl-8-azabicyclo[3.2.1.]-oct-3-yl)-2,3-dihydro-(1- 
methyl)ethyl-2-oxo-IH-benzimidazol-l-carboxamide)]; CGS 12066B, 7-trifluoromethyl-4-(4-l-piperazinyl)-pyrrolo[l,2- 
a]quinoxaline; CHAT, choline acetyltransferase; CP 93129, [3-(l,2,5,6-tetrahydropyrid-4-yl) pyrrolo[3,2-b]pyrid-5-one]; 
5-CT, 5-carboxyamidotryptamine; DA, dopamine DAU 6215, [(endo-N-8-methyl-8-azabicyclo-[3.2.1.]oct-3-yl)-2,3- 
dihydro-2-oxo-lH-benzimidazol-l-carboxamide]; DBB, diagonal band of Broca; (+)-DOI, 1-(2,5-dimethoxy-4- 
iodophenyl)-2-aminopropane; 5,7-DHT, 5,7-dihydroxytryptamine; FG-7080, (--)trans 4-(4-fluorophenyl)-3-(4-rneth- 
oxyphenoxymethyl)piperidine hydrochloride; GR 113808, [1-[2(methylsulphonyl)-amino]ethyl]-4-piperidinyl]methyl-l- 
methyl-lH-indole-3-carboxylate; GR 125487, [1-[2(methylsulphonyl)-amino]ethyl]-4-piperidinyl]-methyl-5-fluoro-2- 
methoxy- 1H-indole-3-carboxylate; GR 127935, N-[4-methoxy-3-(4-methyl-l-piperazinyl)phenyl]-2"-methyl-4"-(5- 
methyl-l, 2,4-oxadiazol-3-yl)[l, 1-biphenyl]-4-carboxamide; 5-HT, serotonin, 5-hydroxytryptamine; H VSA, high-voltage 
spindle activity; IP3, inositol triphosphate; L 694247, 2-[5-[3-(4-methylsulphonylamino)benzyl-l,2,4-oxadiazol-5-yl]-1H- 
indole-3-yl]-ethylamine; LSD, lysergic acid diethylamine; LTP, long term potentiation; LVFA, low voltage fast activity; 
LY 53857, 4-is•pr•py•-7-methyl-9-(2-hydr•xy-•-methy•pr•p•xycarb•ny•)-4•6•6A•7•8•9••••••A-•ctahydr•in-d•••-[4•3- 
FG]-quinolone; mCPBG, 1-(m-chlorophenyl)-biguanide; mCPP, 1-(3-chlorophenyl)piperazine; MDL 72222, 3,5- 
dichlorobenzoic acid,8-methyl-8-azabicyclo[3,2,1]octan-3-YL ester,methanesulfonate, monohydrate; MDL 73005, 
8-(2-[2•3-dihydr•-••4•benz•di•xin-2-y•-methy•amin•]ethy•)-8-azaspir•[4•5]decane-7•9•di•ne; MDMA, 3,4-methylene- 
dioxymethamphetamine; 2-Me-5-HT, 2-methyl-5-hydroxytryptamine, ecstasy; 5-MeO-DMT, 5-methoxy-dimethyl- 
tryptamine; 5-MO-HT, 5-methoxytryptamine; NA, noradrenaline; NAN 190, 1-(2-methoxyphenyl)-4-[4-(2-phtalimido)- 
butyl]piperazine; NBM, nucleus basalis of Meynert, or magnocellularis; 6-OHDA, 6-hydroxydopamine; 8-OH-DPAT, 
8-hydroxy-2-(di-n-propylamino)tetralin; pCA, para-chloroamphetamine; pCPA, para-chlorophenylalanine; RSA, 
rhythmical slow wave activity; RU 24969, 5-methoxy-3-[1,2,3,6-tetrahydi-opyridin-4-yl]- 1H-indole; SB 204070, (l-butyl- 
4-piperidinylmethyl)-8-amino-7-chloro-l,4-benzodioxan-5-carboxylate; TFMPP, N-(3-trifluoromethylphenyl)piper- 
azine; THA, tetrahydroaminoacridine; TTX, tetrodotoxin; WAY 100135, N-tert-butyl-3-(4-[2-methoxyphenyl]piperazin- 
1-yl)-2-phenylpropamide. 
J.-C. Cassel and H. Jeltsch 
CONTENTS 
1. INTRODUCTION 
2. NEUROBIOLOGICAL SUBSTRATES 
2.1. Neuroanatomical approaches 
2.l.1. Serotonergic terminals in cholinergic nuclei or targets 
2.1.2. 5-HT~ receptors 
2.1.3. 5-HT 2 receptors 
2.1,4. Other 5-HT receptors 
2.2. Lesion approaches 
2.3. Electrophysiological approaches 
2.4. Pharmacological pproaches 
2.4.1. Principal receptors considered and characteristics 
2.4.2. In vitro approaches 
2.4.2.1. Hippocampus 
2.4.2.2. Cerebral cortex 
2.4.2.3. Striatum 
2.4.3. In vivo approaches 
2.4.3.1. Hippocampus 
2.4.3.2. Cortex 
2.4.3.3. Striatum 
2.5. Summary and conclusions 
3, COGNITIVE IMPLICATIONS 
3.1. Lesion approaches 
3.l.1. The septohippocampal system 
3.1.2, The basalocortical system 
3.1.3. Conclusions 
3.2. Intracerebral grafting approaches 
3.2.1. Grafts rich in serotonergic and cholinergic neurons 
3.2.2. Grafts rich in serotonergic neurons 
3,2.3. Conclusions 
3.3. Pharmacological pproaches 
3.3.1. Non-selective pharmacological approaches 
3.3.1.1. Cholinergic action in serotonin-depleted animals 
3.3.1.2. Serotonergic action in acetylcholine-depleted animals 
3.3.1.3. Other approaches 
3.3.1.4. Conclusions 
3.3,2. Selective pharmacological approaches 
3.3.2.1. 5-HydroxytryptaminelA receptors 
3.3.2.2. 5-Hydroxytryptamine 2 r ceptors 
3.3.2.3. 5-Hydroxytryptamine 3 r ceptors 
3.3.2.4. Other 5-Hydroxytryptamine receptors 
3.4. Summary and conclusions 
4. GENERAL CONCLUSIONS 
ACKNOWLEDGEMENTS 
REFERENCES 
2 
3 
3 
3 
4 
5 
5 
5 
6 
8 
9 
9 
9 
15 
15 
15 
15 
21 
21 
22 
22 
23 
23 
24 
24 
25 
25 
25 
25 
26 
26 
26 
27 
27 
27 
27 
27 
28 
29 
29 
29 
31 
33 
33 
l. INTRODUCTION 
In the mid-1970s, three independent research 
groups 34"59A72'173'255 reported that the basal forebrain 
from patients with Alzheimer's disease (AD) exhib- 
ited dramatic degeneration of the cholinergic neur- 
ons. This important series of findings has strongly 
stimulated research on the possible relationship be- 
tween cholinergic function in the central nervous 
system and cognitive processes. Interest for an in- 
volvement of cholinergic processes in cognitive func- 
tion had already emerged in the 1960s. However, 
exponential progress in this field started only about 
a decade later ~3 with data from clinical observations, 
psychopharmacological studies in animals and hu- 
mans, and basic neuroscience approaches relying 
upon lesion techniques. 
Animal models of AD have concentrated on the 
cognitive deficits resulting either from lesions of 
cholinergic nuclei or cholinergic pathways, or from 
pharmacological blockade of central cholinergic 
neurotransmission (e.g., Refs 52, 69, 226). Almost all 
experimental (animal or clinical) studies undertaken 
during the 1960s, the 1970s and part of the 1980s 
might nowadays be considered as pointing to one 
conclusion, namely that the disruption of central 
cholinergic functions results in impaired learning and 
memory. These apparently solid and replicable results 
led to the "cholinergic hypothesis of learning", a 
hypothesis that Bartus et al. ~3 have summarized as: 
"it (the cholinergic hypothesis) attempts to explain 
only the most direct, cause-effect relationship associ- 
ated with the primary symptoms (i.e. memory loss)". 
Over the past decade, however, conceptual changes 
and new neurochemical characterization of the neu- 
ropathology of AD (e.g., Refs 32, 86, 129) clearly 
indicated that the "cholinergic hypothesis of learn- 
ing" is too reductionistic: memory processes are not 
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solely a matter of cholinergic processes, even if the 
latter epresent a crucial step in learning and memory. 
Other neurotransmitter systems uch as the dopamin- 
ergic, GABAergic, noradrenergic and serotonergic 
ones are now recognized to be involved in cognition 
and the concept of neurotransmitter interactions (and 
balance) in determining behavior and cognition has 
become a major working hypothesis in behavioral 
neurosciences (e.g., Refs 64, 119, 210, 252). In a 
recent review, Decker and McGaugh 64 suggest hat 
cognition could be regarded as the output from 
various components of an integrated system in which 
several subsystems would share either parallel syner- 
gistic roles (the neurobiological processes occurring 
in parallel in two or more systems which contribute 
to cognition through additive processes) or serial 
interactive roles (different neurotransmitters modu- 
late a given neuronal system to determine a particular 
cognitive faculty). It is also possible that a given 
cognitive function may result from a combination of 
both parallel and serial processes in the brain. 
As stated by Decker and McGaugh 64 in their 
conclusion "while our understanding of the cholin- 
ergic system and its role in learning and memory is 
far from complete, we have progressed to the point 
where it is possible, and necessary, to address the 
importance of the interplay of neurotransmitter sys- 
tems in the modulation of memory processes". With 
regard to such an "interplay", it is clear that research 
must not only be focused on the modifications of the 
behavioral (cognitive) outputs generated by con- 
joined manipulations of different systems of neuro- 
transmitters, but also, on the structural and 
functional characterization of the neurobiological 
substrates which allow interactions among the differ- 
ent neurotransmitters to occur. All the types of 
interactions reviewed by Decker and McGaugh 64 are 
potential concerns for histological, electrophysiologi- 
cal, neurochemical, pharmacological nd behavioral 
approaches. 
Sirvi6 et al. 224 recently reviewed experimental 
studies demonstrating that serotonin has a modula- 
tory role in cognition. In this review, the authors 
mainly focused their attention on their own (enor- 
mous) experimental contribution to this field. In 
addition, they summarized the current knowledge on 
the substrates involved in serotonergic nfluences on 
cognition, but, apart from a large series of psy- 
chopharmacological arguments, they did not tackle 
extensively the experimental approaches which 
allowed this knowledge to emerge. In a review 
paper, the latter aspect may be very helpful to the 
reader. 
The main goal of the present review is to present 
a more general (and perhaps more detailed) overview 
of the neuroanatomical, electrophysiological, phar- 
macological (both in vitro and in vivo) and behavioral 
arguments which demonstrate that serotonergic 
modulation of cholinergic function can be accepted 
as a well (though not exhaustively) documented fact 
of cholinergic function 3 
with structurally identified and functionally charac- 
terized neurobiological substrates. That Steckler 
and Sahga1229 have recently published a review on 
a similar topic (just as the present one had been 
completely revised) might be regarded as indicative 
of the importance that this topic has gained over 
the last few years. 
2. NEUROBIOLOGICAL SUBSTRATES 
2.1. Neuroanatomical pproaches 
To exhaustively review the distribution of the 
various serotonergic and cholinergic nuclei, terminals 
and receptor sites throughout the mammalian brain 
is beyond the scope of the present synthesis. On these 
matters, the reader is referred to review articles on 
serotonergic and cholinergic neuroanatomy, neuro- 
pharmacology and neurophysiology (e.g., Refs 1, 7, 
36, 38, 39, 96, 111, 140, 166, 209, 230, 233, 238, 246, 
253,259). In this section, attention will be focused on 
studies reporting the presence of serotonergic termi- 
nals or 5-hydroxytryptamine (5-HT) receptors in 
brain regions involved in cholinergic function, either 
because these regions are nuclei rich in cholinergic 
cell bodies (e.g., nucleus basalis magnocellularis, me- 
dial septum, diagonal band of Broca, laterodorsal 
and pedunculopontine tegmental nuclei) or because 
they are innervated by cholinergic neurons (e.g., 
cortex, hippocampus, triatum) and, therefore, the 
locus of a potential serotonergic modulation of 
cholinergic function. 
2.1.1. Serotonergic terminals in cholinergic nuclei 
or targets. Using immunohistochemical methods, 
K6hler et al. 113 have found serotonergic fibers in the 
septal nuclei. Whereas the ventral region of the lateral 
septum and a region bordering the medial edge of the 
islands of Calleja contained serotonergic terminals, 
the serotonin immunoreactivity n the diagonal band 
of Broca (DBB) consisted essentially of fibers en 
passage, suggesting that in the DBB, there is no 
substrate for serotonin to influence cholinergic func- 
tion. Using antibodies against serotonin, Milner and 
Veznedaroglu ~43 have demonstrated that the septal 
region of the rat contained numerous 5-HT-immuno- 
positive afferents which formed symmetric (probably 
inhibitory) synapses with the perikarya nd the prox- 
imal dendritic segment, as well as asymmetric (prob- 
ably excitatory) synapses with the distal dendritic 
segment of neurons that were identified as septo- 
hippocampal ones, some of which are likely to 
be cholinergic. Vertes 24° has injected wheatgerm 
agglutinin-conjugated horseradish peroxidase into 
several nuclei of the basal forebrain (including the 
medial septum and the vertical limb of the DBB) 
and found retrogradely labeled neurons in various 
structures of the brainstem including the median 
and dorsal raphe nuclei. This finding suggests that 
some of these projections to the forebrain cholinergic 
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nuclei might be serotonergic. This suggestion was 
supported by Semba et al. 2t9 who combined im- 
munohistochemistry and retrograde labeling tech- 
niques to study the magnocellular basal forebrain 
afferents originating in the brainstem. They found 
that after an injection into both the vertical imb of 
the DBB and the magnocellular preoptic area, a 
small amount of serotonin- and tyrosine hydroxylase- 
positive neurons of the dorsal raphe had been labeled. 
Using similar techniques, Losier and Semba ~24 pro- 
vided additional data demonstrating the presence 
of serotonergic terminals in the basal forebrain, 
although the proportion of serotonergic neurons 
projecting to the basal forebrain was relatively small 
(< 5%). Jones and Cuello ~°7 have reported that after 
an injection of horseradish peroxidase near the basal 
forebrain cholinergic neurons (globus pallidus, sub- 
stantia innominata nd magnocellular p eoptic nu- 
cleus) projecting towards cortical structures, some 
retrograde-labeled neurons were found in the raphe 
nuclei. In addition, these authors described multiple 
serotonin-immunoreactive fibers in the vicinity of 
positive choline acetyltransferase (ChAT)-positive 
neurons of the basal forebrain. In the hippocampus, 
one of the major terminal fields of cholinergic neur- 
ons in the brain, Oleskevich et al. 165 found the 
immunostained 5-HT innervation to be predomi- 
nantly non-synaptic (70 80%), suggesting that sero- 
tonin may exert an axoaxonic modulation of multiple 
types of neurochemical terminals, one of which may 
be GABAergic, another cholinergic. S6gu61a et al. 2~ 
have provided immunocytochemical evidence that 
the "entire cortical volume might actually be within 
reach of the 5-HT transmitter" and that 5-HT might 
exert diverse and widely distributed actions on 
cortical functions. Thus, it is tempting to assume 
that some of the cholinergic neurons innervating the 
cortex might be under such an influence. 
These findings, however, do not demonstrate un- 
equivocally that there are functional links between 
serotonergic terminals and cholinergic neurons in the 
septal area and in other cholinergic nuclei or targets 
of the brain, nor do they provide any information as 
to which type of 5-HT receptor may be considered as 
a potential substrate for these putative connections. 
Additional information may be obtained from studies 
based on autoradiography and in s i tu  hybridization 
techniques. However, the precise identification of a 
receptor subtype supposes the existence of specific 
ligands. As recently reviewed by Hoyer et al. 9~ and 
Martin and Humphrey, TM such ligands do not exist 
for all receptor subtypes and, among the ligands 
which are available, some may bind to more than one 
subtype of 5-HT receptor [e.g., [~25I]lysergic a id 
diethylamine (LSD) recognizes 5-HT~F, 5-HT2A, 5- 
HT2c, 5-HTsA, 5-HTsB, 5-HT 6 and 5-HT 7 receptors, 
all of which are structurally different]. The reader will 
find an updated review of serotonergic receptor 
nomenclature and 5-HT receptor ligands in the article 
by Hoyer et al. 9t (see also Section 3.4.1.). 
2.1.2.  5 -Hydroxyt ryptamine  I receptors .  Quirion 
and Richard, ~v7 using [3H]5-HT, have labeled the 
5-HT t binding sites in the rat brain. They found 
5-HT~ receptors to be especially located in areas that 
are densely innervated by cholinergic (but also dopa- 
minergic) terminals, namely the substantia innomi- 
nata, the ventral pallidum, the striatum, the septal 
nuclei and the hippocampus. Interestingly, a fimbri- 
aectomy induced a more than 50% decrease of 
labeled 5-HT~ receptors in the hippocampus, a find- 
ing that Lawrence et al. 116 failed to replicate in rats 
which received ibotenate or ~-amino-3-hydroxy-5- 
methyl-isoxazole propionate (AMPA) injections into 
the basal forebrain. The latter authors, however, have 
used [3H]8-hydroxy-2-(di-N-propylamino)tetralin (8- 
OH-DPAT) to label receptors of the 5-HTIA subtype 
and their conclusion was that, in the hippocampus 
(but also in the cortex), these receptors are located 
postsynaptically. Zilles et al. 261 have found 5-HT~ 
receptors to also be present in nuclei such as the 
septum, the DBB or the nucleus basalis of Meynert 
(NBM). Chalmers and Watson, 48 combining in s i tu 
hybridization and receptor autoradiography, found 
that, compared to other brain structures, the medial 
septum and the vertical diagonal band exhibited 
high levels of both 5-HT~A mRNA and 5-HTtA 
binding sites. Interestingly, these two markers were 
also found in various regions of the cortex (frontal, 
frontoparietal, cingulate and entorhinal cortices) 
and in the hippocampus, but neither was found in 
the caudate nucleus or in the nucleus accumbens. 
Overall, in the structures exhibiting high levels of 
5-HTIA mRNA and 5-HTIA binding sites, there was 
a complementary distribution of these two markers, 
suggesting that this receptor might have both a 
presynaptic autoregulatory and a postsynaptic 
regulatory role in serotonergic neurotransmission. 
Other studies have also shown both 5-HT~A mRNA 
and binding sites to be present in the dorsal raphe, the 
septum, the hippocampus and the entorhinal cortex, 
as well as in the cerebral cortex, but at a lower density 
than in the former cerebral regions. ~76 Sijbesma 
et al. 22° have compared the distribution of several 
subtypes of 5-HT receptors in the brain of the rat and 
the guinea-pig. They found high levels of 5-HTIA 
receptors in the neocortex and the hippocampus of 
both species with, however, some species differences 
in the relative amounts of these receptors. For in- 
stance, in regions CA I/CA2 of the hippocampus and 
in the dorsal subiculum, the level of 5-HTIA receptors 
was higher in the guinea-pig than in the rat. Con- 
versely, in the dorsolateral septum, the cingulate 
cortex and the neocortex (laminae IV and V), the 
level of 5-HT~A receptors was higher in the rat. 
In the basal forebrain of the guinea-pig, Khateb 
et al. 1°9 have provided pharmacological evidence 
for a serotonergic modulation of the cholinergic 
neurons in the nucleus basalis which involves 5-HTIA 
receptors. Additional evidence is obtained from 
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experiments based on electrophysiological or lesion 
approaches ( ee below). 
Pazos and Palacios 17° have reported 5-HTm recep- 
tors to be present in the basal ganglia, the substantia 
nigra and the subiculum of the rat, a finding that 
Sijbesma et al. 22° have confirmed. In the mouse brain, 
Boschert et al. 3~ have compared the distribution of 
5-HTtB mRNA and 5-HT~B binding sites. They report 
high levels of 5-HT1B mRNA in the caudate-putamen, 
but not in the globus pallidus and the substantia nigra 
where high levels of 5-HTIB binding sites were found. 
In the hippocampus there was also a mismatch 
between the localization of the mRNA and that of the 
corresponding protein, as high levels of 5-HT~B 
mRNA were found in region CA1 of Ammon's horn, 
whilst the highest levels of binding sites were found 
in the subiculum. In the septal area, these authors 
found moderate levels of 5-HT~B mRNA and weak 
amounts of 5-HTIB binding sites, suggesting that in 
this brain region, the mRNA coding for the 5-HT~B 
receptor is not associated with cholinergic projection 
sites. In the guinea-pig, a species in which 5-HT~B 
receptors do not exist (e.g., Refs 31, 244), 5-HT~D 
receptors were found to be distributed according to 
a pattern which resembles that of the 5-HT~B ones in 
the rat. This is an interesting observation as both 
5-HT~B and 5-HT~D receptors may share comparable 
roles in different species. TM There are, however, a few 
exceptions in that the substantia nigra, the ventral 
pallidum and the globus pallidus present relatively 
more 5-HT~B receptors in rats than 5-HT~D sites in 
guinea-pigs. Conversely, in the claustrum, the dorsal 
endopiriform nucleus and the dentate gyrus, the level 
of 5-HT~D receptors in guinea-pigs i  higher than that 
of 5-HT~B receptors in rats (e.g., Ref. 220). 
2.1.3. 5-Hydroxytryptamine2 receptors. Rat stria- 
tum and nucleus accumbens exhibit high densities of 
5-HT 2 receptors whereas in the cortex and in the 
hippocampus, this density is low (see also Ref. 23). 225 
Quirion et al. 178 have measured [3H]ketanserin bind- 
ing, a marker for 5-HT 2 receptors, in the anterior 
cortex, the middle cortex and in the striatum of rats 
which had sustained lesions of the nucleus basalis. 
These authors found that the number of 5-HT 2 
receptors was reduced in both the anterior ( -42%)  
and middle ( -35%)  cortex, but not in the striatum, 
suggesting that in the cortex, there is a certain 
proportion of these sites located on cholinergic ter- 
minals and which could potentially serve as the 
substrate for serotonergic-cholinergic interactions. 
A reduction in the number of 5-HT 2 receptors has 
also been reported in patients who died from AD, j82 
as well as in aged rats. ~53 The patients with AD 
exhibited a reduction in cortical cholinergic markers 
as well as a diminished binding of [3H]ketanserin.182 
This decrease of ketanserin-binding sites does not 
necessarily result from the degeneration of cholin- 
ergic neurons possessing serotonergic receptors; ero- 
tonergic neurons might be concerned as well. 
However, Reynolds et al. ~82 could not show a signifi- 
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cant reduction in cortical serotonin or 5-hydroxyin- 
dolacetic acid concentrations, uggesting that in 
patients with AD, the serotonergic tone, at least in 
the cerebral cortex, might be relatively well-preserved 
(e.g., Ref. 74). 
Although in the initial report by Morilak and 
Ciaranello, ~47 few 5-HT2 receptors were found to be 
located in the basal forebrain or striatum, the suc- 
ceeding study found that one of the most abundant 
population of neurons possessing 5-HT 2 receptors 
was in the basal forebrain) 48Thus, part of the pattern 
of 5-HT 2 receptors in the rat brain overlapped with 
that of cholinergic neurons or terminals (e.g., in the 
caudate-putamen or the basal forebrain) and some of 
the 5-HT2-positive neurons displayed morphological 
features which were comparable to those of the 
cholinergic ell population in these nuclei. ~48 
2.1.4. Other 5 -hydroxytryptamine receptors. 5-HT 3 
receptors have been found in brain regions where 
dendrites, cell bodies or terminals of cholinergic 
neurons are present. These regions include the en- 
torhinal cortex, the hippocampus and the nucleus 
accumbens, as well as other regions of the forebrain 
(e.g., Refs 8, 9, 12, 35, 110, 245, 248). 5-HT 4 receptors 
have been detected, using autoradiography, in the 
hippocampus, triatum and substantia nigra of rat 
and guinea-pig. 25 As mentioned in the review by 
Martin and Humphrey, TM messenger RNA coding for 
5-HTsA receptors was found in rat cortex and hippo- 
campus. 5-HTsB mRNA was detected in the habenula 
and in limited regions of the hippocampus (CAI). 
5-HT 6 mRNA has been discovered in the striatum, 
the olfactory tubercule, the cortex and the hippo- 
campus. 5-HT 7 mRNA has been identified in the 
thalamus, the hippocampus and discrete regions of 
the limbic system. 
Thus, there are structures in the mammalian brain 
in which both cholinergic and serotonergic neu- 
roanatomical substrates can be identified. These 
structures include the basal forebrain nuclei (DBB, 
septal region, nucleus basalis), the laterodorsal nd 
pedunculopontine t gmental nuclei, the hippo- 
campus, the striatum and at least some cortical areas. 
However, the general picture lacks precision, essen- 
tially because the histological or morphological ob- 
servations often indicate possibilities rather than 
certitudes. This lack, however, will be partially offset 
by the results of the more functional approaches 
described in Sections 2-4. 
2.2. Lesion approaches 
Decker and Thai 65 have analysed the effects of 
separate or combined lesions of the NBM (ibote- 
nate) or of the dorsal raphe nucleus 5,7-dihy- 
droxytryptamine (5,7-DHT) on cholinergic and 
serotonergic functional markers in the rat frontal 
cortex. They report that NBM lesions reduced the 
release of acetylcholine by about 50% without 
affecting that of serotonin, raphe lesions reduced 
the 5-HT release by 49% without affecting that of 
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acetylcholine, and that both lesions trictly combined 
these ffects. Their conclusion was that the serotoner- 
gic projections arising in the dorsal raphe do not play 
any role in the regulation of neocortical tonic release 
of acetylcholine. After intraventricular infusion of 
5,7-DHT, Alonso and Soubri62 determined the den- 
sity of muscarinic receptors in both the hippocampus 
and the cerebral cortex and reported these markers to 
be unchanged. This result would also indicate that 
there is no direct link between serotonergic and 
cholinergic terminals in the cortex or the hippo- 
campus. However, Alonso and Soubri62 have found 
that the scopolamine-induced upregulation of hippo- 
campal and cortical muscarinic receptors was totally 
blocked by 5,7-DHT lesions, an observation that 
would support an interaction between the sero- 
tonergic and cholinergic systems, but essentially in 
terms of serotonergic modulation of "muscarinic 
plasticity". 
That serotonergic mechanisms might be involved 
in muscarinic plasticity is also suggested in the report 
by Earley et  al. 7° in olfactory bulbectomized rats, 
these authors have demonstrated that the density 
of muscarinic receptors was elevated in the amyg- 
daloid cortex, the basal ganglia, the hippocampus, 
the hypothalamus, the cortex and in olfactory re- 
gions. The density of 5-HT2 receptors was increased 
in the cortex, the hippocampus and the thalamus. 
Interestingly, these authors also found that a 35-day- 
long systemic treatment with mianserin, a 5-HT2 
antagonist, or desipramine, a noradrenaline re- 
uptake inhibitor, attenuated not only the sero- 
tonergic upregulation i duced by the lesion, but also 
the muscarinic one. 
Quirion and Richard t77 have measured the density 
of 5-HT~ receptors in various regions of the rat brain 
after lesions of either the area including the NBM and 
the substantia innominata (kainic acid injections) or 
the fimbria and the fornix (transection). They report 
that NBM lesions had no effect on the density of the 
cortical 5-HTI receptors, conversely to fimbria fornix 
transections which reduced the density of 5-HT~ 
receptors by more than 50% in the hippocampus. The 
authors uggest that 5-HT l receptors may be present 
at the cholinergic terminals of neurons originating in 
the septal nuclei. However, fimbria-fornix lesions 
also disrupt serotonergic, GABAergic and other ros- 
tral innervation sources of the hippocampus (as well 
as hippocampal efferents) and the results reported by 
Quirion and Richard, ~77 therefore, should not be 
regarded only as a consequence of the cholinergic 
denervation of the hippocampus. This caution is of 
particular importance since Fischette et al. v2 have 
reported that selective lesions of serotonergic neurons 
also decreased the 5-HTI receptors in the anterior 
hippocampus (by about 35% in the dentate gyrus and 
regions CA3-CA4). In addition, the findings by 
Quirion and Richard Ivy do not show which receptor 
subtype of the 5-HTt class is concerned. According to 
more recent findings, it is probably not the 5-HTIA 
type. Indeed, Lawrence et al. ll6 examined 5-HTIA 
receptors in the rat cortex and hippocampus after 
cholinergic or serotonergic lesions and concluded that 
these receptors are not located on either cholinergic 
or serotonergic nerve terminals. This finding, how- 
ever, does not preclude that a functional serotonin- 
acetylcholine link exists, which may be mediated by 
receptors other than the 5-HTIA ones (in the rat, the 
5-HT~ receptor class also covers 5-HTla , 5-HTlc 
(now called 5-HT2c), 5-HTID and 5-HTIr sites, 91'131 
although the distribution of these subtypes does 
not necessarily correspond to that of cholinergic 
terminals in the brain). 
Lown et al. ~25 have compared the effects of lesions 
of either the dorsal and median raphe or the NBM 
and found that serotonergic lesions (raphe) have no 
effect on the level of 5-HTIA and 5-HT 2 receptors in 
the frontal cortex, whereas cholinergic lesions (NBM) 
increase the level of cortical 5-HTIA and 5-HT 2 
receptors, suggesting that a functional interaction 
may exist between the serotonergic and cholinergic 
functions in the frontal cortex of rats. The finding 
that after NBM lesions the number of cortical 5-HT 2 
receptors i increased is in line with earlier eports by 
Quirion et al. 178 and by Wenk and Engisch. TM If one 
turns to the early study by Robinson, 2°7 such a link 
really seems to exist and can be demonstrated by 
lesion techniques of the mesencephalic serotonergic 
nuclei. After 5,7-DHT-induced estruction of the 
dorsal raphe, he found that the acetylcholine 
turnover was increased both in the hippocampus and 
the cortex, but not in the striatum, suggesting that 
the serotonergic neurons from the dorsal raphe pro- 
duce a tonic inhibition of cholinergic function in the 
cortex (as do neurons of the median raphe) and the 
hippocampus (an effect not mediated by neurons of 
the median raphe). 
Another approach consists of determining the sero- 
tonergic receptors in cholinergic-denervated regions. 
Muramatsu et al. TM showed that following a lesion of 
the medial septum, the binding of [3H] ketanserin was 
reduced in the hippocampus, whilst that of [3H]5-HT 
or [3H]8-OH-DPAT was not, a finding suggesting 
that the cholinergic terminals in the hippocampus 
possess 5-HT 2 receptors, but not 5-HTIA ones (this 
conclusion is corroborated by a functional approach 
presented hereafter). 
2.3. E lect rophys io log ica l  approaches  
There is a large series of studies howing that, in 
various regions of the mammalian brain known to 
contain cell bodies, dendrites or terminals of cholin- 
ergic neurons, a local application of serotonergic 
drugs, or even a serotonergic lesion, may influence the 
electrophysiological activity of the "resident" cell 
population. Depending on the brain region con- 
sidered, this influence may involve various subtypes 
of serotonergic receptors (e.g., Refs 6, 24, 25, 97, 
136, 154, 171, 187, 216, 231, 238, 241). However 
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only a few articles in the literature provide clear 
arguments demonstrating that an interaction be- 
tweenserotonergic and cholinergic mechanisms may 
have functional consequences that can be detected 
electrophysiologically. 
Richter-Levin and Sega119° have investigated the 
effects of 5,7-DHT-induced serotonin depletion and 
partial lesions of the medial septum on feedforward 
inhibition in the dentate gyrus of rats. Feedforward 
inhibition is defined as the blockade of the response 
of the dentate gyrus to perforant path stimulation by 
prior stimulation of the hippocampal commissural 
pathway. These authors found that neither type of 
lesion affected feedforward inhibition. However, a 
combination of both lesion types, resulted in reduced 
feedforward inhibition, an effect that could be re- 
versed by intrahippocampal grafts containing sero- 
tonergic neurons. Interestingly, aged rats also display 
reduced feedforward inhibition. 191'192 
Semba et al. 219 combined immunohistochemical 
and retrograde tracing methods with an electro- 
physiological pproach to investigate the activity of 
neocortical neurons after stimulation of a region 
including the raphe nucleus. They showed that such 
a stimulation was able to modulate the activity of 
some neocortical neurons, probably via cholinergic 
neurons located in the horizontal limb of the DBB or 
in the magnocellular p eoptic area receiving afferents 
from the raphe nucleus. However, it must be empha- 
sized that only a minority of the latter afferents were 
found to be immunoreactive to serotonin. 
Vanderwolf and Baker 237 have used another ap- 
proach. They measured low-voltage fast activity 
(LVFA: 10-50 Hz, maximal amplitude 0.5 mV) in the 
cortex and rhythmical slow wave activity (RSA: 
7-12Hz, amplitude depending on the electrode's 
location) in the hippocampus of rats submitted to 
various pharmacological treatments (control, at- 
ropine and/or parachlorophenylanine (pCPA), or 
other drug treatments). Cerebral activity in both the 
cortex and the hippocampus i  controlled by cholin- 
ergic and serotonergic nputs. These inputs are con- 
currently active during mobility (spontaneous waking 
behaviors defined as type 1 behaviors) and generate 
RSA in the hippocampus as well as LVFA in the 
cortex. As stated by Vanderwolf and Penava, 239 the 
activity of these inputs appears to be smaller during 
awake immobility (type 2 behaviors) and RSA disap- 
pears in the hippocampus, whereas LVFA can often 
be observed in the cortex. When experimental manip- 
ulations inactivate either the serotonergic or the 
cholinergic input, the hippocampal and the cortical 
activities are modified, although they keep some 
characteristics of RSA and LVFA during type 1 
behaviors. When both inputs are inactivated simul- 
taneously, RSA and LVFA are no longer observed 
during mobility. These data, nevertheless, do not 
demonstrate that the modifications observed after 
concurrent serotonergic and cholinergic inactivations 
are partly or completely due to the disruption of a 
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serotonergic control of cholinergic function. The data 
rather suggest hat both neurotransmitter systems 
may co-operate, perhaps in parallel, in generating 
RSA and LVFA during mobility. In an earlier study, 
Peck and Vanderwolf had shown that scopolamine- 
induced muscarinic blockade partly antagonized the 
effects of raphe stimulations on RSA and LVFA, a 
finding that also suggests both systems to co-operate 
in the determination f RSA and LVFA. That also an 
interaction with electrophysiological relevance might 
be possible is suggested by some data from the next 
experiment. In 1 3 out of 1 6 animals, Vanderwolf and 
Baker 237 have found that pCPA-treated rats exhibited 
normal RSA (i.e. to motor activity and atropine-sen- 
sitive). However, in the three remaining pCPA- 
treated rats, the electrophysiological correlates of 
activated septohippocampal cholinergic pathways 
showed an abnormal profile: RSA was of lower 
frequency (5-7 Hz vs 6-12 Hz) and appeared uring 
immobility. Since immobility RSA is normally resist- 
ant to atropine (and therefore is not mediated by 
muscarinic receptors), the observations reported in 
these three animals suggest that the serotonergic- 
depletion might have influenced the functionality of 
the septohippocampal cholinergic system. This con- 
clusion is in line with an earlier experiment 138 showing 
that after serotonergic lesions (5,7-DHT), hippocam- 
pal theta activity could be elicited by septal stimu- 
lations of lower intensity than that necessary in the 
septum of unlesioned animals. Recently, however, 
Leung et al. 118 have published data showing that 
pCPA treatment in rats with septal esions does not 
change the hippocampal theta pattern compared with 
the pattern found after septal esions only. 
Dringenberg and Vanderwolf 68 have recorded tran- 
scallosal evoked potentials (single pulse stimulation 
of the deep contralateral neocortex) in rats submitted 
to antiserotonergic (ketanserin, methiothepin) and/or 
antimuscarinic (scopolamine) drug treatments. A
typical evoked potential consisted of an initial nega- 
tive component and a subsequent positive one. After 
methiothepin i jections (5 mg/kg, i.p.), the authors 
found the initial component to be increased in dur- 
ation and amplitude, an effect hat they also observed 
after scopolamine injections (5 mg/kg, i.p.). Whereas 
the amplitude of this early component was further 
increased when scopolamine was given in conjunction 
with methiothepin (same doses), its duration was 
reduced to about one half the values observed in the 
no drug condition. Ketanserin also had some effect. 
However, this effect was less pronounced than after 
methiothepin i jections. Furthermore, it was appar- 
ent only on the duration of the late component of 
the evoked potential during immobility and could 
be reversed by scopolamine treatment. 
Riekkinen eta / .  198 have recorded the electroen- 
cephalographic activity of the neocortex. In rats, 
they describe this activity as consisting of desynchro- 
nized low voltage fast activity during mobility and 
high-voltage spindle activity (HVSA; 6-10 Hz, 
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synchronized over both hemispheres) during waking 
immobility. Riekkinen et al. 198 found that whereas 
5,7-DHT lesions of the dorsal raphe had no effect on 
HVSA, lesions of the NBM resulted in increased 
HVSA, an effect that is also found after scopolamine 
treatment. 2°° When both lesions were combined, the 
increase of HVSA was found to be larger than after 
only NBM lesions. The latter finding suggests that in 
the neocortex, a functional interaction between both 
the cholinergic and serotonergic systems might, in 
some respects, be involved in the generation of 
HVSA. Interestingly, an increase of HVSA has also 
been found in aged rat, 2°° but this latter increase was 
resistant to ondansetron (GR 38032F), methysergide 
and alaproclate treatments. 
Using another model, Luebke et al. Iz6 have com- 
bined a histochemical pproach with intracellular 
and whole-cell patch-clamp recording techniques to 
assess whether cholinergic neurons in the laterodorsal 
tegmental nucleus of the rat showed an electrophysio- 
logical activity which was subjected to serotonergic 
modulation. These authors provided evidence that in 
this nucleus, more than half of the spontaneously 
bursting cholinergic neurons responded to appli- 
cation of serotonin with membrane hyperpolariz- 
ation, an effect that could be closely mimicked with 
a 5-HT~A receptor agonist. These findings demon- 
strate that in this nucleus, serotonin exerts an inhibi- 
tory influence upon cholinergic neurons by acting on 
5-HTIA receptors. Levkovitz and Sega112~ have inves- 
tigated the electrophysiological reactivity of the hip- 
pocampal system to stimulation of the perforant 
pathways (entorhinal afferents) and found that sys- 
temic administration of fenfluramine, a serotonin 
releaser, increased the population spike response 
resulting from perforant path stimulation. This po- 
tentiating effect of fenfluramine was inhibited by 
atropine pretreatment in a dose-dependent manner. 
Interestingly, the fenfluramine-induced effect could 
be mimicked by physostigmine injections and blocked 
by spiperone. These findings how that the potentiat- 
ing effect of fenfluramine may be the result of an 
interaction involving cholinergic and serotonergic 
mechanisms in the hippocampal formation. Hong 
and Krnjevic 9° reported that, when iontophoretically 
applied to the region CA1 of the rat hippocampus, 
5-HT was able to inhibit the acetylcholine-induced 
facilitation of population spikes induced by an 
electrical fimbrial-commissural stimulation. 
Finally, there are also studies showing that 
serotonergic and cholinergic mechanisms may be 
conjointly involved in long-term potentiation (LTP) 
phenomena. Maeda et al. ~28 have studied LTP in 
the mossy fiber-CA3 system of the guinea-pig 
hippocampus. Using hippocampal slices, they 
demonstrated that an application of l-(m- 
chlorophenyl)-biguanide (mCPBG) or 2-methyl-5- 
hydroxytryptamine ( cstasy, 2-Me-5-HT), two 5- 
HT~ receptor agonists, attenuated the magnitude 
of LTP, whilst an application of granisetron, a 5- 
HT 3 antagonist, increased this magnitude (see also 
Ref. 167). Interestingly, the latter effect could be 
weakened by the muscarinic antagonist atropine 
applied at a concentration that had no effect by 
itself. 
Altogether, these experiments suggest hat a co- 
operation or even an interaction between the sero- 
tonergic and cholinergic systems may have functional 
consequences that can be detected with electrophysio- 
logical recording techniques in at least the cortex and 
the hippocampus. This is also true in humans (e.g., 
Ref. 139). The most convincing data, however, come 
from pharmacological experiments. These exper- 
iments will be described in detail in the next section. 
2.4. Pharmacological approaches 
In the middle of the 1970s, a series of experiments 
demonstrated the existence of a functional link be- 
tween serotonergic and cholinergic neurons in the rat 
striatum. The first demonstration that serotonin 
could influence the activity of cholinergic neurons 
was reported by Butcher et al. in 1976. 4o These 
authors showed that rats pretreated with para- 
chlorophenylalanine (pCA) or lesioned in the dorsal 
raphe nucleus exhibited a decreased rate of striatal 
acetylcholine synthesis. Supportive data came from 
the studies by Euvrard et al., 71 Guyenet et al., 8° and 
Samanin et  al . ,  214 who all showed that systemic 
administration of serotonin agonists increased the 
acetylcholine content in the rat striatum, suggesting 
that serotonin isexerting an inhibitory modulation of 
cholinergic function in the striatum. 
Since that time, essentially three regions of the 
brain receiving both a serotonergic and a cholinergic 
innervation have been investigated with in vitro and 
in vivo methods: the hippocampus, the cortex and the 
striatum. These investigations allowed the identifi- 
cation and the characterization f some pharmaco- 
logical substrates of the link between serotonergic 
and cholinergic functions in the mammalian brain. 
As regards the influence of serotonin on the release 
of acetylcholine, the type of modulation (activatory, 
inhibitory) as well as the type of receptor involved in 
this modulation were found to depend upon several 
factors including the species (e.g., rat vs guinea-pig), 
the brain region (e.g., hippocampus v striatum) and 
the methods used to perform the experiments (e.g., 
in ~,itro vs in vivo). In vitro experiments essentially 
investigated the effects of drug applications to tissue 
slices or synaptosomes preloaded with [3H]choline 
and subsequently exposed to potassium or electri- 
cal stimulation. In vivo experiments investigated 
the effects of drugs delivered locally or adminis- 
tered systemically on acetylcholine content (post 
mortem analysis) or release (microdialysis) in various 
cholinergic targets. 
Thus, the in vitro experiments mainly characterized 
the serotonergic mechanisms modulating cholinergic 
function by an action occurring at the level of 
the cholinergic terminal. These mechanisms involve 
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either heteroceptors located on the cholinergic termi- 
nals (i.e. a direct modulatory action) or receptors 
located on terminals other than cholinergic ones 
which are able to influence the release of a neuro- 
transmitter to which cholinergic function is also 
sensitive (i.e. an indirect modulatory action). Con- 
versely, the in vivo approaches howed effects of 
serotonin on cholinergic function which may not only 
be due to direct pre- and/or postjunctional ctions, 
but which may also result from activation or inhi- 
bition of complex polysynaptic loops, especially 
when i.c.v, or systemic administrations of substances 
affecting the serotonergic systems are used. 
2.4.1. Principal receptors considered and character- 
istics. Basically, the in vitro and in vivo pharmacologi- 
cal studies have investigated the involvement of 
5-HT1A, 5-HTIa, 5-HTID, 5-HT2, 5-HT 3 and 5-HT 4 
receptors in the modulation of central cholinergic 
function. For each family of 5-HT receptors, oper- 
ational, structural and transductional specificities 
have been described. 91'13L Briefly, in the brain, the 
5-HTIA receptor is predominantly postsynaptic, 
although it was identified as a somatodendritic re ep- 
tor in raphe neurones. The 5-HTIA receptor couples 
to multiple G proteins with preferential mediation 
by the inhibition of adenylyl cyclase (e.g., Ref. 81). 
There are numerous agonists available, but the most 
useful 5-HTIA agonist is 8-OH-DPAT. The number of 
selective antagonists is more limited and, with excep- 
tion of WAY 100135 (see Ref. 131), they all seem to 
have partial agonist activity. Transductional charac- 
teristics imilar to those of the 5-HT~A receptor are 
also found for 5-HT~a and 5-HT~D receptors. The 
5-HT~a is the autoreceptor involved in presynaptic 
regulation of serotonin release in the rat brain (e.g., 
Refs 142, 228), a role that might be assumed by 
5-HT~D receptors in the human and guinea-pig brain 
(e.g., Ref. 93). The 5-HTIB receptor also functions as 
a terminal heteroreceptor controlling the release of 
neurotransmitters other than serotonin. The com- 
pound CP 93129 is a selective agonist of the 5-HT1B 
receptor, sumatriptan and L 694,247 of the 5-HTID 
receptor. There is no good selective antagonist for the 
5-HT~B receptor, GR 127935 being an antagonist of 
the 5-HT~D receptor. 5-HT 2 receptors are divided into 
three subclasses (5-HT2A , 5-HTzB and 5-HT2c ) and 
are coupled to phospholipase C. Their activation 
leads to stimulation of phosphatidyl inositol and 
results in an increased IP 3 production (e.g., Ref. 122). 
There is neither a selective agonist nor a selective 
antagonist for any of the three subtypes of 5-HT2 
receptors. Among other substances, alpha-Me- 
5-HT is a non-selective 5-HT2 agonist, ketanserin, 
ritanserin, mesulergine and LY 53857 being non- 
selective 5-HT 2 antagonists. The 5-HT 3 receptor is 
coupled to an ionic channel regulating the Na+/K + 
conductance ( .g., Ref. 234). Agonists of this receptor 
type are 2-Me-5-HT and m-chloro-phenylbiguanide, 
the most potent one being 3,3,5-trichloro-phenyl- 
biguanideJ 46 Antagonists are tropisetron, ondan- 
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setron, granisetron and zacopride. Finally, the 5-HT 4 
receptor iscoupled to adenylyl cyclase, but positively. 
5-HT 4 agonists are 5-methoxytryptamine, renzapride, 
BIMU 1 and BIMU 8. Antagonists are GR 113808 
and SB 204070. All these transductional character- 
istics, agonists and antagonists of the various 5-HT 
receptor types have been presented in more detail in 
recent reviews. 91'~3~ 
2.4.2. In vitro approaches. In vitro experiments 
carried out on slices or synaptosomes prepared from 
specific brain regions of rats, guinea-pigs or humans 
are summarized in Table 1. 
2.4.2.1. Hippocampus. One consensus to emerge 
is that, in the hippocampus of both the rat and 
the guinea-pig, an application of serotonin, in the 
1-100/~M range, produces a significant inhibition of 
evoked (induced by exposure to supranormal concen- 
trations of potassium or by electrical field stimu- 
lations) release of acetylcholine. Depending upon the 
studies and the concentration of serotonin applied, 
the reported inhibition was generally found to vary 
between 10 and 40%. Since no effects of serotonin 
have been described on the baseline release of acetyl- 
choline from slices or synaptosomes, it can be con- 
sidered that the serotonin-induced inhibition is 
operating when the cholinergic neurons are active. 
The most likely type of 5-HT receptor mediating 
the inhibitory action of serotonin on acetylcholine 
release is from the 5-HT1 class (for an updated 
nomenclature, see Refs 91 and 131). Several argu- 
ments support this assertion (see Table 1 for de- 
tails). First, the inhibitory effects of serotonin can 
be mimicked by application of agonists showing 
some affinity for the 5-HT 1 receptor [e.g., l-(3- 
chlorophenyl)piperazine (mCPP), RU-24969, N-(3- 
trifluoromethylphenyl) piperazine (TFMPP)]. 
Second, the inhibitory effects of serotonin are abol- 
ished or dramatically attenuated under the influ- 
ence of 5-HT~ antagonists. For instance, the inhibi- 
tory effect of TFMPP, a non-selective agonist of 
5-HT receptors, is reduced by application of mi- 
naprine, a 5-HT 1 antagonist, or by that of other 
antagonists having an affinity for both the 5-HT~ 
and 5-HT 2 sites. Minaprine itself is able to influence 
the release of acetylcholine by activating protein 
kinase C. 47 
In the rat, this inhibitory heteroceptor appears to 
belong to the 5-HT~B type. This is in agreement with 
the report by Maura and Raiteri m who first demon- 
strated that the inhibitory effect of serotonin is 
mediated by a 5-HT 1 receptor, who then showed 
that neither 5-HTjA nor 5-HT2¢ receptors were 
involved, and who therefore concluded that the 
5-HT~B receptor might be implicated (see also 
Ref. 180). Their conclusion was supported by 
observations that CGS 120966B, a rather selective 
5-HT~B agonist, concentration-dependently inhibited 
the evoked release of acetylcholine from rat 
hippocampal synaptosomes. 27'28 In addition, we 
recently found that CP 93129, a 5-HTtB agonist, 
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concentration-dependently decreased the electrically 
evoked release of acetylcholine from hippocampal 
slices (unpublished observations). 
8-OH-DPAT, a specific agonist of 5-HT~A recep- 
tors, did not affect the evoked release of acetylcholine 
(see Refs 84, 134, 151, and personal unpublished 
observations). 
As to other classes of 5-HT receptor (i.e. 5-HTIo, 
5-HT~E and 5-HTIF), all of which are found in 
the rat brain, 91'131 no data as regards preparations 
of rat hippocampus exposed to specific agonists 
or antagonists are, to our knowledge, currently 
available. 
The involvement of 5-HT 2 receptors (i.e. 5-HT2A, 
5-HT2B and 5-HT:c) has also been excluded since: (i) 
application of 5-HT 2 agonists uch as (___)-DOI or 
quipazine does not affect the evoked release of acetyl- 
choline; and (ii) application of 5-HT 2 antagonists 
such as ketanserin, methysergide or spiperone (the 
two latter drugs also act on 5-HT~ sites) does not 
abolish the inhibitory effect of 5-HT, 5-HT uptake 
inhibitors or 5-HT agonists on acetylcholine r lease 
from hippocampal preparations. 
Finally, there are a few indications suggesting that 
5-HT 3 receptors do not seem to be critically involved 
in a direct presynaptic regulation of acetylcholine 
release by serotonin. In the presence of MDL 72222, 
a 5-HT 3 antagonist, he non-selective 5-HT agonist 
TFMPP was still able to reduce the potassium- 
evoked release of acetylcholine from hippocampal 
synaptosomesfl 9 However, this reduction was smaller 
( -  28%) than in the absence of MDL 72222 (--43%). 
Although the participation of 5-HT 3 receptors in 
regulation of hippocampal acetylcholine release 
cannot be excluded, it is probably not of critical 
importance. 
In conclusion, the principal receptor involved in 
serotonin-induced inhibition of acetylcholine r lease 
in the rat hippocampus seems to belong to the 5-HTm 
type. In the hippocampus of guinea-pigs where the 
5-HT~B receptors do not exist (e.g., Ref. 220), the 
inhibitory serotonergic heteroceptor might be of the 
5-HT~D type (see Table 1). 
2,4.2.2. Cerebral cortex. Bianchi et alf l  ° reported 
that a high concentration f serotonin produced only 
a small inhibition of electrically evoked release of 
acetylcholine from slices of guinea-pig cerebral cor- 
tex. Barnes et al. ~° reported that in the rat entorhinal 
cortex serotonin alone had no effect on acetylcholine 
release. However, the co-application of serotonin and 
ritanserin, a 5-HT 2 antagonist, resulted in a 50% 
decrease of potassium-induced release of acetyl- 
choline. Whereas the 5-HT 3 agonist, 2-me-5-HT, had 
no effect when applied alone, addition of ritanserin 
produced an effect comparable to that found with 
serotonin and ritanserin. In addition, the evoked 
release was increased by 107% when 2-me-5-HT was 
applied in the presence of ondansetron, a 5-HT3 
antagonist, and by 37% in the presence of zacopride, 
another 5-HT 3 antagonist. Both these facilitatory 
effects were prevented by addition of ritanserin. 
These results, however, do not demonstrate that 
5-HT 3 receptors are directly involved since a con- 
comitant action on the 5-HT 2 receptor seems to be 
required to observe a modulation of cholinergic 
function via the 5-HT 3 receptor. Moreover, Johnson 
et al.~°6 failed to replicate some of the effects described 
by Barnes et al. ~° In an in v i tro study using human 
frontal, temporal and occipital cortex fragments, 
Maura et al. 133 found serotonin to inhibit potassium 
evoked release of synaptosomal cetylcholine in a 
dose dependent manner, with a maximum of -56% 
at 10#M. This inhibition was prevented by tropi- 
setron and ondansetron, two specific 5-HT 3 antagon- 
ists, but not by spiperone or ketanserin, two drugs 
blocking the 5-HT 2 receptor. Altogether, the results 
indicate differences among species as to the modu- 
lation of acetylcholine r lease from cerebral cortex by 
5-HT receptors. 
2.4.2.3. Striatum. In the striatum, serotonin has 
also been found to modulate cholinergic function 
(Table 1). Using striatal slices, Vizi et al. 242 reported 
that the ouabain-induced stimulation ofacetylcholine 
release was reduced by exposure to d-fenfluramine, a 
5-HT releaser, as well as to piperazine, a non-selective 
5-HT agonist. These effects of d-fenfluramine and 
piperazine were not observed in rats which sustained 
5,7-DHT lesions of the serotonergic neurons but 
were still present after 6-OHDA-induced depletion of 
the dopaminergic neurotransmission. When sero- 
tonergic antagonists such as mianserin, methysergide 
or cyproheptadine w re applied to the slices during 
stimulation, the acetylcholine r lease was enhanced 
by more than 100%. 242 Serotonergic agonists or 
5-HT-uptake inhibitors blocked the electrically- 
evoked release of acetylcholine. 77'95 The receptor in- 
volved in this modulatory effect of serotonin might be 
of the 5-HT~ or 5-HT 2 type as methysergide, cypro- 
heptadine, cinanserin and mianserin, which do not 
distinguish between these subtypes, antagonized this 
effect. 77 
In the guinea-pig striatum, Bianchi et al. 2~ reported 
that application of 5-HT elicited a biphasic response 
from cholinergic neurons. First, they rapidly re- 
sponded by increasing (approx. + 50%) the release of 
acetylcholine, an effect which was sensitive to 
tetrodotoxin (TTX) and, then, the release decreased 
below baseline (approx. -27%),  an effect which was 
insensitive to TTX. The authors provided some ex- 
perimental rguments (Table 1) that the facilitatory 
phase involved a direct activation of 5-HT2 receptors 
located on cholinergic terminals, whereas the inhibi- 
tory phase was mediated via a 5-HT-induced modu- 
lation of dopamine release, a neurotransmitter to 
which cholinergic terminals in the striatum are also 
sensitive. 88
2.4.3. In vivo approaches.  In vivo experiments hat 
demonstrate the influence of serotonin on cholinergic 
function are summarized in Table 2. 
2.4.3.1. Hippocampus. Administration of drugs 
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modifying serotonergic functions in the brain were 
found to alter the release of acetylcholine from rat 
hippocampus. For example, Consolo et al. 54 and 
Nilsson et aL 156 reported that serotonin release en- 
hancers (e.g., fenfluramine, norfenfluramine or pCA) 
or uptake inhibitors (e.g., citalopram), injected i.p., 
more than doubled acetylcholine r lease (Table 2; see 
also Ref. 55). These observations are in line with 
earlier findings of Samanin et alf114 who found qui- 
pazine to alter (but not necessarily to increase) the 
hippocampal content of acetylcholine. 
Conversely, the systemic administration f a sub- 
stance which increases the uptake of serotonin (i.e., 
tianeptine), thereby reducing the synaptic availability 
of serotonin, reduced the release of hippocampal 
acetylcholine, j8 However, when drugs acting directly 
on serotonergic receptors were infused into the 
hippocampus, 94 they did not necessarily activate 
cholinergic function as was found with systemic 
serotonergic treatments ( ee above), although Ohue 
et al. ~64 reported intrahippocampal infusions of 
high concentrations (drugs infused through the 
dialysis probe) of serotonin to enhance the release 
of acetylcholine, an effect which was mimicked 
by 5-methoxy-dimethyltryptamine (5-MeO-DMT) 
(1 mM), a non-selective s rotonergic agonist. 
According to Izumi et al. 94 two types of receptors 
having opposite ffects may be involved in the sero- 
tonin-induced modulation of cholinergic function, 
that is, 5-HTIA receptors enhanced and 5-HT m recep- 
tors attenuated the release of acetylcholine. Both 
these effects were obtained with intrahippocampal 
infusions of the drugs, suggesting that these effects 
originated irectly in the hippocampus. The 5-HTtB- 
mediated effect is in line with in v i tro findings (see 
previous section) and might imply a pre-junctional 
mechanism. An involvement of 5-HT~ A receptors in 
facilitation of hippocampal cetylcholine r lease has 
also been found in guinea-pigs 256 with the substances 
being administered systemically (8-OH-DPAT); this 
effect, however, was not observed when the drug was 
administered through the dialysis probe, suggesting 
that the 8-OH-DPAT-induced effect does not orig- 
inate in the hippocampus. In this study, sumatriptan, 
a 5-HTjD agonist, had no effect, an interesting obser- 
vation since this receptor seems to be the inhibitory 
heteroreceptor oncholinergic terminals in the guinea- 
pig hippocampus ( ee previous ection). Facilitation 
of hippocampal cetylcholine r lease has also been 
described as being mediated by 5-HT 3 receptors in, at 
least, the rat2 4 Indeed, systemic administration of
5-HT 3 agonists was found to enhance cholinergic 
function in the hippocampus and this effect was 
abolished by the co-administration f 5-HT 3 antag- 
onists such as ondansetron or DAU 6215. Since all 
these drugs were administered i.p., s.c. or i.c.v., it 
cannot be concluded that this 5-HT3-mediated ffect 
has pharmacological substrates only in the hippo- 
campus, even if 5-HT 3 receptors are present in the 
hippocampus, a6°Indeed, one possibility would be that 
NSC 69/1~" 
activation of 5-HT 3 sites occurs elsewhere in the brain 
and, via one or more neurons interposed between the 
serotonergic terminals and the cholinergic targets, 
induces an increased efflux of acetyicholine. Another 
type of serotonergic receptors found in the hippo- 
campus 26° is the 5-HT4 receptor. As recently shown by 
Consolo et al., 53 this receptor might also be involved 
in serotonergic modulation of hippocampal cholin- 
ergic function. However, this receptor, in contrast to 
the 5-HT3 receptor, is inhibitory as regards the efflux 
of acetylcholine in the hippocampus. 53'54 This study, 
as with others based on systemic drug administration, 
does not allow us to conclude that the 5-HT4-medi- 
ated inhibition has its substrate located only within 
the hippocampus. 
2.4.3.2. Cortex. A serotonin-mediated influence on 
cholinergic function has also been found in both the 
rat and guinea-pig cortex. In the guinea-pig, using 
an epidural cup to collect acetylcholine, Bianchi 
et al. 2° have shown that i.c.v, administration f 5-HT 
induced an increase of acetylcholine release. This 
effect was abolished after 5,7-DHT-induced sero- 
tonergic depletion in the brain, but neither pCPA, 
nor systemic methiothepin affected this response; 
d-Norfenfluramine (i.p.) also had no effect. 
Bianchi et al., 22 using a microdialysis technique to 
collect acetylcholine, have shown that i.c.v, or s.c. 
injection of 8-OH-DPAT, a 5-HTIA agonist, dose- 
dependently increased the cortical etItux of acetyl- 
choline, whereas i.c.v, injection of 2-Me-5-HT, a 
5-HT 3 agonist, decreased this release, Both these 
effects could be antagonized with drugs that block the 
5-HT 3 receptor (see Table 2); ketanserin, a 5-HT 2 
antagonist, had no effect. 5-HT~A receptors also 
facilitated the release of cortical acetylcholine in 
rats, 223 although with a lower sensitivity than in the 
guinea-pig and with a method based on collection of 
epidurally applied Ringer solution. When less specific 
drugs were used, such as for instance a serotonin 
uptake activator administered systemically (e.g., 
tianeptine), Bertorelli et al. TM found the cortical efflux 
of acetylcholine to be decreased in rats. 
In the rat, activation of 5-HT receptors by i.c.v. 
administration f BIMU 1 or BIMU 8, two selective 
5-HT4 agonists, enhanced cortical release of acetyl- 
choline, an effect which was fully abolished by co-ad- 
ministration of a selective 5-HT 4 antagonist. 53 
Although 5-HT 4 receptors have been found in the 
rat cortex, the route of drug administration (i.c.v.) 
does not allow to conclude whether the substrates of
this enhancing effect are located in the cortex or 
elsewhere in the brain. Nevertheless, it is noteworthy 
that activation of 5-HT4 receptors enhances acetyl- 
choline release in the cortex but decreases it in the 
hippocampus. 
2.4.3.3. Striatum. Finally, a modulatory influence 
of serotonergic agents upon the cholinergic function 
has also been found in the striatum as demonstrated 
in the early reports by Butcher et al., 4° Euvrard 
et al., 71 Guyenet et al. 8° and Samanin et al. 214 Overall, 
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these pioneering findings suggested that serotonin 
was able to inhibit cholinergic function in the stria- 
turn. On rats submitted to post  mor tem determi- 
nations of striatal acetylcholine content, Samanin 
et al. 2~4 found that systemic treatment with quipazine, 
a 5-HT uptake inhibitor, or d-fenfluramine, a 5-HT 
release activator, both injected prior to being killed, 
resulted in increased acetylcholine concentrations in 
the striatum (+ 33% and + 51%, respectively). This 
effect was completely blocked by pretreatment with 
mixed 5-HTI/5-HT 2 antagonists (metergoline and 
cinanserin). Consolo et al. 55 have observed that sys- 
temic injections of fenfluramine induced an increased 
release of acetylcholine in the nucleus accumbens (but 
not in the brainstem). In the same report, these 
authors also showed that systemic fenfluramine in- 
creased striatal acetylcholine content, suggesting that 
the striatal cholinergic neurons are under inhibitory 
control of serotonergic neurons. Although Bertorelli 
el al. TM could not influence the efflux of striatal 
acetylcholine with i.p. injections of tianeptine, a 5-HT 
uptake activator, Rada et al. 179 have shown that 
infusion of 5-HT as well as of fluoxetine, an inhibitor 
of 5-HT uptake, resulted in a lower aeetylcholine 
etttux. Since this effect was prevented by propranolol, 
a mixed 5-HTi//3-adrenergic antagonist, and mim- 
icked by 8-OH-DPAT, a selective 5-HT~A agonist, it 
is possible that the inhibitory effect of serotonin on 
cholinergic function in the striatum is mediated by a 
5-HTIA receptor. 
2.5. Summary  and  conc lus ions 
This series of results may be summarized as fol- 
lows. With histological approaches, ome regions of 
the brain were found to receive both a serotonergic 
and a cholinergic innervation. These regions include 
the striatum, the cortex and the hippocampus. Many 
studies have shown that an interaction between sero- 
tonergic and cholinergic processes in one or the other 
of these regions may result in physiological modifi- 
cations that the manipulation of only one of these 
systems is unable to mimick qualitatively or quanti- 
tatively. The majority of the arguments demonstrat- 
ing that an interaction between cholinergic and 
serotonergic processes have a functional relevance 
and were obtained with pharmacological approaches. 
These pharmacological studies showed that in rat 
hippocampus, acetylcholine release is inhibited by 
activation of intrinsic 5-HTIB and perhaps 5-HT3 
receptors and, under the condition of a systemic 
activation, can be facilitated via 5-HT~A as well as 
5-HT3 receptors, or inhibited via 5-HTIB (5-HT m in 
the guinea-pig) and 5-HT 4 receptors. In the cortex, 
the release of acetylcholine may be locally controlled 
by 5-HT 3 inhibitory receptors, whereas ystemic acti- 
vation of 5-HTIA and 5-HT 4 receptors results in 
facilitation. Finally, in the striatum, local inhibition 
may be mediated by 5-HT l and/or 5-HT2 receptors 
and, under the condition of systemic activation, by 
5-HTIA receptors. These data are summarized in 
Table 3, which may be considered as a provisional 
state of knowledge about the neurobiological sub- 
strates that may be involved in the serotonergic 
control of cholinergic function in the cortex, the 
hippocampus and the striatum. 
All these possible sites through which serotonin is 
able to influence cholinergic activity in the brain are 
potential substrates where an interaction between 
serotonergic and cholinergic neurobiological pro- 
cesses may potentially influence cognitive function, 
especially in terms of learning and memory. The next 
section will deal with the experimental rguments 
supporting the view that cognitive function does, in 
some respects, depend upon an interaction between 
serotonergic and cholinergic function. The non-cog- 
nitive implication of the central serotonergic systems 
(e.g., appetite, circadian rhythmicity, nociception, 
sleel>wakefulness, exual behavior) are also well 
documented in the literature, but lay beyond the 
scope of the present review (information can be found 
in Refs 49, 58, 78, 105, 141, 149, 185, 232, 249). 
3. COGNITIVE IMPLICATIONS 
Many experiments have investigated the involve- 
ment of central cholinergic function in cognitive 
processes (e.g., reference list in Refs 52, 69, 221,226). 
Similarly, many studies (some being over 30 years 
old) have also examined the potential involvement of
serotonergic systems in learning, memory and, more 
generally, cognition (e.g., Refs 43, 101, 115, 123, 137, 
163, 224, 243, 257, 258). However, apart from the 
Table 3, Receptors involved and effect of serotonergic modulation of cholinergic function in the 
hippocampus, the cortex and the striatum 
Brain region 
Methods Hippocampus Cortex Striatum 
In vitro (presynaptic) Inhibitory Inhibitory Inhibitory 
5-HTIB"/5-HT3 h 5-HTf 5-HT I/5-HT 2 
5-HT 2 
In vivo (systemic) Inhibitory Inhibitory 
5-HT~B/5-HT 4 5-HTta 
Facilitatory Facilitatory 
5-HT~A/5-HT 3 5-HT~A/5-HT 4 
~5-HTID in the guinea-pig; %ffect weak but significant in the rat; ¢controversed in rodents, demonstrated 
in humans. 
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contribution by Smith 227 (see below), the interaction 
between serotonergic and cholinergic systems has 
only been consistently considered for about 10 years 
as having a potential cognitive relevance and, conse- 
quently, investigated more extensively. These exper- 
iments have mostly used lesion, grafting and 
pharmacological approaches. One of the first reviews 
dealing with that topic was by Segal et al. in 1989, 2~7 
but this book chapter was essentially restricted to the 
cognitive functions of the hippocampus. In addition, 
since 1989, many other experiments have been per- 
formed and these have also been reviewed in another 
very recent article. 229 
3.1. Lesion approaches 
For many years, experiments in behavioral neuro- 
biology have used lesion techniques that selectively 
damage well delineated regions of the brain (nuclei, 
pathways of target structures) in order to assess the 
behavioral correlates of this damage. An approach 
based on neurochemical selectivity of the lesions has 
become possible only with the emergence of a series 
of compounds with neurotoxic properties oriented 
towards neurochemically-defined populations of 
neurons. For instance, 6-hydroxydopamine (6- 
OHDA), a substance that selectively destroys cat- 
echolaminergic neurons, was discovered in the late 
1960s TM and was used extensively to study the func- 
tional involvement of central dopaminergic neurons 
and to set up a relevant animal model of Parkinson's 
disease. Subsequently, Baumgartner and collabor- 
ators (e.g., Refs 14, 15, 16) introduced 5,6-DHT and 
5,7-DHT, two other substances that were able to 
damage the serotonergic neurons (when noradren- 
ergic neurons are protected by desipramine). The 
latter compound, 5,7-DHT, which proved to be more 
useful, has been used extensively to selectively destroy 
serotonergic neurons in the brain and to investigate 
the functional correlates of such specific lesions. As 
regards the cholinergic system, AF64A has opened 
some promising perspectives, but the specificity of 
this substance has been firmly questioned (e.g., Refs 
73, 82, 83, 127). Nevertheless, it seems that under 
conditions of appropriate dosage, 72 the toxic effects of 
AF64A might reach a satisfactory degree of specifi- 
city. Another compotmd has emerged recently which 
appears to be much more specific for cholinergic 
neurons in at least the forebrain. It is an im- 
munotoxin oriented towards the nerve growth factor 
receptor, 192IgG-saporin (e.g., Refs 17, 30, 87, 157). 
So far, however, and to our knowledge, no exper- 
iment has been published about the behavioral corre- 
lates of combined serotonergic and cholinergic lesions 
performed with 5,7-DHT and 192 IgG-saporin, re- 
spectively. Therefore, the present section will focus on 
a series of experiments hat have combined classical 
lesion techniques (e.g., electrolysis, thermocoagula- 
tion or intracerebral injections of excitatory amino 
acids) disrupting the cholinergic fibers of the basal 
forebrain with serotonergic depletion techniques uti- 
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lizing 5,7-DHT, pCPA or pCA. 127 The two latter 
compounds are administered systemically and induce 
dramatic depletions of central serotonergic function 
by inhibiting the synthesis of serotonin (pCPA) or by 
destroying the serotonergic terminals (pCA), while 
5,7-DHT, which is administered into the cerebral 
ventricles or parenchyma, induces neuronal degener- 
ation by acting on the neuronal cell bodies (e.g., Refs 
127, 222). The serotonin depletion induced by pCPA 
and pCA is reversible. This may be a drawback in 
experiments a sessing long term effects. Among other 
drawbacks of these compounds, it should be noted 
that pCPA may induce catecholaminergic alterations 
in most regions of the brain. Also, it does not affect 
all functional markers of the serotonergic innervation 
(i.e. 5-HT uptake sites are preserved66). Thus, when 
pCPA is used to damage serotonergic neurons, ex- 
treme caution must be taken in interpreting the 
physiological and/or behavioral effects found (are 
they really due to serotonergic lesions? What may be 
the contribution of non-specific toxicity?). Even if 
pCA is more selective than pCPA, it is noteworthy 
that its administration i itially results in increased 
release of serotonin and not in serotonergic depletion 
(e.g., Ref. 108) Thus, appropriate post-adminis- 
tration delays must be used. Another possible draw- 
back is that pCA seems to work only on mature 
serotonergic neurons, l°s Finally, whether or not 
pCA induces true nerve terminal degeneration is still 
subject o debate 127 (but see Ref. 66). 
The various approaches combining different ypes 
of lesions are based on a principle that consists of 
comparing the cognitive ffects of separate serotoner- 
gic or cholinergic depletion with the cognitive ffects 
found when both these depletions are realized to- 
gether. The underlying idea of these approaches i  the 
following: if a serotonergic/cholinergic interaction 
has cognitive relevance, the combined depletions 
should induce behavioral effects that are different 
(generally more marked) from those induced by each 
depletion performed separately. The septohippocam- 
pal and the basalocortical cholinergic systems have 
been investigated with this rationale. 
3.1.1. The septohippocampal  system. Nilsson 
et al. ~Ss have compared some behavioral effects of 
cholinergic lesions (by radiofrequency) in the medial 
septum (note that septal lesions also damage fibers en 
passage such as, for instance, those from the cortex 
to the nucleus accumbens), serotonergic lesions per- 
formed with intraventricular injections of 5,7-DHT, 
and both types of lesions combined. To assess cogni- 
tive performance in their rats, Nilsson et al. Is8 used 
the Morris water-maze according to a protocol as- 
sessing spatial reference memory. The authors found 
that, in rats with only 5,7-DHT lesions, the spatial 
learning abilities were not significantly altered, whilst 
rats with only septal lesions exhibited an impaired 
ability to find the platform. However, it is noteworthy 
that, in the rats given both lesions combined, the 
deficit was significantly larger than that found after 
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only septal lesions. Richter-Levin and Segal ~9° re- 
ported data showing that neither a partial electrolytic 
lesion of the medial septum, nor an intraventricular 
injection of 5,7-DHT impaired water-maze perform- 
ance, whether with a reference memory testing pro- 
cedure or a working memory one. However, when 
both lesions were combined, both the reference and 
working memory performances were dramatically 
impaired. In contrast, in a passive-avoidance task, the 
rats treated with 5,7-DHT (whether alone or com- 
bined with septal esions) showed better performance 
than intact control rats or rats given only a septal 
lesion. More recently, Murtha and Pappas ~$2 used 
N-methyl-D-aspartate microinjections to disrupt the 
cholinergic neurons in the medial septum and/or 
5,7-DHT (infused in the fimbria-fornix and the cin- 
gulate bundle) to destroy the serotonergic innervation 
of the hippocampus. Their rats were tested in a 
water-maze and a radial-maze with testing pro- 
cedures assessing working and reference memories. 
They found that in the water-maze r ference memory 
test, only the combination of both lesions impaired 
performance. In the water-maze working memory 
test, an impairment was observed only in the group 
with combined lesions when a delay of one minute 
separated two consecutive trials. With a 10-min de- 
lay, a deficit also emerged in the rats with only septal 
lesions. As regards radial maze performance, all rats 
learned the reference memory task. However, during 
the first block of five trials, the rats with only septal 
lesions showed impaired performance when com- 
pared to the unlesioned rats, but those with combined 
lesions showed an impairment exceeding that of the 
septal rats. When tested for working memory, the rats 
with either combined or only septal lesions were 
impaired over 25 trials, but did not differ from one 
another. When testing was continued, however, the 
rats with only septal lesions came closer to the 
performance of the unlesioned controls, a trend 
that was not observed in the group with combined 
lesions. 
3.1.2. The basalocortieal system. Normile et al. 162 
used rats that sustained ibotenate-induced l sions of 
the NBM alone or in combination with systemic 
administration f pCA. Subsequently, these authors 
assessed the acquisition of a complex spatial discrimi- 
nation task in a Stone 14-unit T-maze. They found 
that the rats given pCA alone showed better perform- 
ance than their unlesioned counterparts. Although 
NBM lesions had no effect on spatial earning, they 
prevented the pCA-induced improvement. Riekkinen 
et al. 2°~ have compared the effects of separate or 
combined lesions of the dorsal raphe and the NBM 
on acquisition of a water-maze task in rats. The 
authors report he dorsal raphe lesions to be ineffec- 
tive, the NBM lesions to impair performance and 
both lesions combined to induce an impairment 
greater than that due to NBM lesions alone. Using 
passive-avoidance and water-maze tasks, J~k~il~i et 
al.1°° have investigated the behavioral effects of either 
NBM lesions produced by quisqualic acid injections, 
inhibition of brain serotonin synthesis performed 
with systemic pCPA treatment, or both types of 
lesions combined. They found that NBM lesions 
severely impaired passive-avoidance retention and 
only slightly disturbed water-maze performance. 
PCPA alone had no effect in either of these tasks, but 
potentiated the effects of NBM lesions. Markowska 
and Wenk ~3° also compared the behavioral effects of 
NBM lesions (injection of ibotenic acid) combined or 
not with serotonin depletion induced by systemic 
pCA treatment, but they used a nonspatial memory 
task (cued delayed non-matching to sample task) and 
paid attention to both the acute and long-term effects 
of the experimental treatments ( ee also Ref. 251). 
They found that serotonin depletion had no effect on 
behavioral performance, whether shortly (four 
weeks) after treatment or later on, when testing was 
prolonged. In contrast, NBM lesions produced an 
impairment in the non-spatial memory task. Com- 
bined pCA treatment and NBM lesions did not 
produce a larger deficit than NBM lesions alone. 
However, when testing was prolonged, rats with 
NBM lesions showed some improvement over time, 
whereas those given both NBM lesions and pCA 
treatment did not. Overall, the effects of NBM lesions 
combined with serotonin depletion on a delayed 
non-matching to sample task appear to be rather 
weak, a conclusion which is in line with another 
report by Sahgal and Keith m who also used a 
delayed non-matching to sample paradigm in rats 
given NBM lesions combined to 5,7-DHT-induced 
serotonin depletion. 
3.1.3. Conclusions. Thus, this series of experiments 
suggests that the cognitive ffects of cholinergic den- 
ervation of the hippocampus ( eptal esions) or the 
neocortex (nucleus basalis lesions) can be exacerbated 
by concomitant serotonin depletion. Another con- 
stant finding in the aforementioned series of exper- 
iments is that serotonin depletion alone does not 
produce detrimental effects on spatial and non- 
spatial working or reference memory processes. 
When effects on memory are observed after sero- 
tonin depletion, these effects even consist of an 
improvement of mnesic performance in some tests 
(e.g., Refs 3, 162). 
In the first part of this review, we have emphasized 
that serotonin could either inhibit (e.g., via presyn- 
aptic mechanisms involving heteroceptors) or facili- 
tate (e.g., via polysynaptic loops with a postsynaptic 
start point) release of acetylcholine. Such mechanisms 
are present in both the hippocampus and the cortex 
(see 2.4.2.1. to 2.4.2.2.), although they do not necess- 
arily involve the same types of pre- or postsynaptic 
receptors (Table 3). Whatever these mechanisms may 
be, all aforementioned xperiments converge towards 
the conclusion that there may be a serotonergic 
modulation of cholinergic function implicated in 
spatial reference and working memory, as well as 
in non-spatial memory. This conclusion is further 
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supported by experiments u ing techniques consisting 
of grafting neuroanatomically and/or neurochemi- 
cally defined populations of neurons into denervated 
structures of the brain. The next seciion will review 
some of the most significant contributions about 
intracerebral transplantation. 
3.2. Intracerebral grafting approaches 
Basically, intracerebral grafts are performed in 
order to provide an experimentally denervated brain 
structure with a new innervation originating from 
the grafted fetal "neurons. Although the mechanisms 
by which such grafts exert functional effects may 
be multiple (e.g., Ref. 44), an appropriate selection 
of the anatomical origin of the fetal neurons may 
help to replace some of the neurochemically-defined 
afferents disrupted by the lesion. For instance, 
fimbria-fornix lesions remove a large part of the 
cholinergic, noradrenergic, GABAergic and sero- 
tonergic afferents of the hippocampus (e.g., Refs 45, 
46, 75, 76, 102, 104, 112, 114), aswell as hippocampal 
efferent pathways. Such lesions are considered as a 
possible animal model of AD (e.g., Refs 52, 69, 204). 
Concerning the "replacement" of the cholinergic 
afferents, the grafts are prepared from the region of 
the fetal brain including the medial septum and the 
DBB, the normal source of the cholinergic inner- 
vation of the hippocampus. As concerns the "replace- 
ment" of the serotonergic afferents, the grafts are 
prepared from the mesencephalic raphe, the nor- 
mal source of the serotonergic innervation of the 
hippocampus (e.g., Refs 45, 46, 103, 155). 
3.2.1. Grafts rich in serotonergic and cholinergic 
neurons. There are several articles based on a grafting 
approach which clearly suggest that a serotoner- 
gic/cholinergic interaction may have cognitive rel- 
evance, as was the case for the lesion approaches 
summarized above. For instance, in rats given lesions 
of the medial septum and intracerebroventricular 
injections of 5,7-DHT, Nilsson et al. ~55 have studied 
the behavioral effects of septal grafts alone (rich in 
cholinergic neurons), raphe grafts alone (rich in sero- 
tonergic neurons), and of a combination of both 
types of grafts. All grafts were placed into the hippo- 
campus and cognitive function was assessed in a 
Morris water-maze according to a reference memory 
testing protocol, Whereas neither type of single grafts 
produced beneficial effects on water-maze perform- 
ance, the combined grafts improved water-maze per- 
formance, but only 10 months after grafting, Using a 
different lesion paradigm (i.e. electrolytic lesions of 
the fimbria and the dorsal fornix), we also found that 
combined septal and raphe grafts placed into the 
denervated hippocampus of rats were able to improve 
(even to normalize) water-maze probe trial perform- 
ance (reference memory protocol), an effect that 
neither of the single grafts was able to produce. Such 
co-grafts, however, failed to improve spatial working 
memory assessed in a radial maze task. 45'1°3 
3.2.2. Grafts rich in serotonergie neurons. Richter- 
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Levin et al. 186 used a lesion paradigm similar to that 
used by Nilsson et al) 55 but performed grafts of only 
mesencephalic raphe cells into the hippocampus or 
the entorhinal cortex. They found the raphe grafts to 
exert beneficial effects on water-maze performance 
(reference memory), but only when implanted within 
the hippocampus; when implanted into the entorhinal 
cortex, a region linked to the hippocampus via the 
perforant path, there was no beneficial effect of the 
grafts. Thus, in the latter experiment, a serotonergic 
reafferentation of the hippocampus deprived of its 
cholinergic and serotonergic afferents was sufficient 
to induce beneficial effects on spatial memory. In a 
recent experiment (unpublished observations) assess- 
ing the effects of fetal raphe neurons implanted into 
the dorsal hippocampus of rats with fimbria-fornix 
lesions, we found the grafted rats to show spatial 
working memory performances which, over 32 trials, 
had reached a level close to that found in the 
sham-operated rats (unpublished observations). In 
another experiment, Richter-Levin and Segal ~s9 have 
combined 5,7-DHT lesions with intrahippocampal 
grafts of mesencephalic raphe. They found that rats 
treated in this way performed similarly to the intact 
control rats in a water-maze task. However, systemic 
treatment with a subamnestic dose of atropine 
(20 mg/kg, i.p.) induced a clear-cut deficit in lesion- 
only rats, but no deficit was observed in either the 
intact control rats or in the rats with 5,7-DHT- 
induced lesions and intrahippocampal grafts. These 
observations were confirmed by another study of 
Richter-Levin and Segal.Jg° Among other aspects, this 
latter study 19° differed from the aforementioned one Is9 
by the fact that the intrahippocampal raphe grafts 
performed in 5,7-DHT lesioned rats partially pre- 
vented a water-maze performance deficit elicited by 
systemic (i.p.) atropine treatment, but at a dose of 
25 mg/kg. 
3.2.3. Conclusions. Altogether, these data provide 
additional support o the view that serotonergic and 
cholinergic afferents to the hippocampus may interact 
and that this interaction has cognitive relevance. 
Actually, following a combined cholinergic and sero- 
tonergic denervation of the hippocampus, grafts 
providing the denervated hippocampus with new 
cholinergic and serotonergic innervations induce a 
better ecovery than the grafts providing the hippo- 
campus with only one or the other of these inner- 
vations. Under some circumstances, it seems that 
even the sole serotonergic reinnervation of the hippo- 
campus may be sufficient to promote significant 
recovery of spatial reference as well as working 
memory performance (but see Ref. 103). Also, sero- 
tonin-depleted rats with a new graft-derived sero- 
tonergic innervation of the hippocampus are more 
resistant o the disruptive effects of an antimus- 
carinic drug than are their lesioned non-grafted 
counterparts. 
However, while all these data demonstrate an 
implication of serotonergic and cholinergic processes 
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in cognitive function, and perhaps may fit with the 
idea of a serotonergic modulation of some cognitive 
abilities in which cholinergic mechanisms have been 
recognized to play an important role, they do not 
contribute to the pharmacological characterization f 
the substrates involved (e.g., where in the brain, 
which systems and which receptors?). 
In the next part of this review, attention will be 
focused on experiments that contribute to such a 
characterization. 
3.3. Pharmacological  approaches 
3.3.1. Non-select ive pharmacological  approaches. 
3.3.1.1. Cholinergic action in 5-hydroxytrypta- 
mine-depleted animals. Vanderwolf, in one of the first 
such studies, evaluated both the passive-avoidance 
and water-maze learning performance in intact or 
pCPA-treated rats exposed to scopolamine (5 mg/kg, 
s.c.) or atropine (50 mg/kg, t.p.) during acquisition or 
retention trials. TM Scopolamine disrupted acquisition 
more than retention, an effect mimicked by atropine. 
pCPA was ineffective, but scopolamine produced a 
larger deficit in pCPA-treated rats than in intact rats. 
In a recent book chapter, other contributions by 
Vanderwolf and colleagues have been summarized. 239 
They all point to the conclusion that the cognitive 
effects of muscarinic blockade may be potentiated by 
serotonergic depletion. Similar findings were reported 
by Richter-Levin and Segal ~88 who combined pCPA- 
induced 5-HT depletion and systemic atropine 
(20 mg/kg, i.p.) treatment before testing their rats in 
the water-maze task. They observed that this sub- 
threshold ose of atropine disrupted spatial earning 
performance only in pCPA-treated rats. More re- 
cently, Matsuno et al. ~32 have found that a pCA- 
induced impairment in passive-avoidance learning in 
mice could be partially reversed by the adminis- 
tration of tetrahydroaminoacridine (efficient dose: 
10mg/kg, p.o.) or physostigmine (efficient doses: 
0.25 and 0.5 mg/kg, i.p.), two acetylcholinesterase 
inhibitors. 
Riekkinen et al. 2°3 have tested intact and 5,7-DHT- 
treated rats for water-maze performance after scopo- 
lamine (0.8mg/kg, i,p.) or pilocarpine (muscarinic 
agonist; 4 and 10 mg/kg, i.p.) treatment. While 5,7- 
DHT lesions produced no deficit, scopolamine 
severely impaired spatial earning in both intact and 
lesioned rats. In intact rats, the scopolamine-induced 
deficit was abolished by pilocarpine treatment at a 
dose of 4 mg/kg (i.p.), whereas in the lesioned rats, a 
dose of 10 mg/kg was necessary to counterbalance the 
scopolamine effect. Thus, a 5-HT depletion decreases 
the efficacy of pilocarpine to reverse a scopolamine- 
induced spatial reference memory deficit. In another 
study, 1% Riekkinen et al. have reported that scopo- 
lamine (0.8mg/kg, i.p.) and alaproclate (7.5 and 
20 mg/kg, i.p.) were able to impair water-maze navi- 
gation performance. Furthermore, the combined in- 
jections of scopolamine (0.8 mg/kg) and alaproclate 
(20 mg/kg) produced a greater impairment than after 
only scopolamine treatment. This effect could be 
partially reversed with administration of pilocarpine 
(6 mg/kg). A subamnestic dose of atropine has also 
been described to produce cognitive perturbations 
in rats given 5,7-DHT into the ventricles or directly 
into the fimbria-fornix, while unlesioned rats showed 
normal performance. 187'19~ Riekkinen et al.  197 have 
also demonstrated that nicotinic receptors may be 
involved in the cholinergic-serotonergic egulation of 
cognitive function. Indeed, this group ~97 has investi- 
gated the effects of mecamylamine (10 mg/kg, i.p.) in 
rats with massive serot0nin depletion (pCPA) on 
passive-avoidance and water-maze performances. 
Neither performance was affected by pCPA treat- 
ment. Given alone in intact rats, mecamylamine 
delayed spatial learning in the water maze but did not 
affect passive avoidance. In pCPA-treated rats, how- 
ever, mecamylamine induced a marked deficit in 
passive avoidance. Later on, Riekkinen et al. 193 re- 
ported a study in which they investigated the effects 
of mecamylamine (7.5 g/kg, i.p.) in pCPA-treated rats 
on working memory in a water-maze and on a 
passive-avoidance r sponse. They confirmed that 
pCPA did not affect water-maze navigation or 
passive-avoidance p rformances and showed that 
mecamylamine impaired (slightly) working memory 
and (substantially) passive-avoidance p rformances 
in intact rats. This effect was counterbalanced or
attenuated by nicotine treatment (0.3 mg/kg, i.p.). In 
pCPA-treated rats, the mecamylamine-induced im- 
pairment was more pronounced and the preventive 
effect of nicotine was less marked than in the intact 
rats. Riekkinen et al.  199 have reported medial septal 
lesions to impair performance in both a passive- 
avoidance and a water-maze learning task. These 
deficits were aggravated by a pCPA-induced sero- 
tonin depletion which, alone, did not affect learning. 
Pre-training trial injections of tetrahydroamino- 
acridine (THA; 1, 3 and 5 mg/kg, i.p.) or nicotine 
(0.03, 0.1 and 0.3 mg/kg, i.p.) attenuated the deficit 
of septal rats at the respective doses of 3 mg/kg 
(THA), 0.1 and 0.3 mg/kg (nicotine) in both tasks. 
In rats which had sustained both a septal esion and 
a serotonin depletion, only THA was found to exert 
beneficial effects. 
Using rats, Jfik/il~i et al. 99 have examined the effects 
of pCPA and/or scopolamine treatment on atten- 
tional processes measured in the five-choice serial 
reactional time test. This test measures an animal's 
ability to detect and respond to brief flashes of light 
presented in one of five food-rewarded locations. The 
authors found that scopolamine (0.2 mg/kg, i.p.) did 
not alter the discriminative accuracy (proportion of 
appropriate locations detected among all responses) 
in the rats which did not sustain pCPA-induced 
lesions. Under standard test conditions (intensity of 
visual stimulus and speed of presentation fixed), the 
discriminative accuracy of pCPA-treated rats tended 
to decrease. Addition of scopolamine treatment did 
not further impair pCPA-treated rats. Only when 
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stimulus intensity was reduced or speed of presen- 
tation increased did pCPA-treated rats present 
impaired accuracy. A weak behavioral effect of con- 
current serotonergic and cholinergic manipulations 
has also been reported by Robinson et al. 2°8 in a 
water-maze learning task, thus on spatial reference 
memory processes. These authors induced a long- 
lasting serotonergic depletion by treating rats with 
high doses of 3,4-methylenedioxymethamphetamine 
(MDMA; "ecstasy") and found serotonin-depleted 
rats to perform similarly to intact control rats. In 
addition, MDMA-treated rats showed a sensitivity to 
systemically administered atropine (50 mg/kg, i.p.) 
that did not differ from that of intact rats. The 
authors interpret hese weak effects as being due to 
insufficient depletion of cortical serotonin ( -73% in 
the neocortex, -32% in the caudate nucleus). 
3.3.1.2. Serotonergic action in acetylcholine- 
depleted animals. Smith 227 has shown that lesions of 
both the medial and the lateral septum--the former 
being rich in cell bodies of cholinergic neurons-- 
facilitated acquisition of a shuttle-box avoidance 
task, and that this facilitation could be reversed 
in rats given 5-hydroxytryptophan (105mg/kg). 
Smith 227 interpreted this result as due to 5-hydroxy- 
tryptophan-induced restoration of the footshock 
sensitivity, a sensitivity which is decreased by the 
serotonergic depletion resulting from the lateral 
and medial septal lesions. However, an alternative 
interpretation might be that the observed effects 
in lesioned 5-hydroxytryptophan-treated rats are 
related to the restoration of some modulatory 
mechanisms involving both acetylcholine and 
serotonin. 
In a book chapter, Vanderwolf and Penava 239 
summarized the main results of the Vanderwolf 
paper, 236 but also an experiment in which rats were 
submitted to a swim-to-platform test after concurrent 
manipulations of the serotonergic and cholinergic 
systems with various types of serotonergic antagon- 
ists and scopolamine. A scopolamine dose of 5 mg/kg 
(s.c.) impaired performance. Ritanserin (0.1, 1, 
10 mg/kg, i.p.), methysergide (5, 10, 20mg/kg, i.p.) 
and pizotifen (10, 2 mg/kg, i.p.) failed to affect the 
severity of the scopolamine-induced deficit at the 
doses indicated. At 5 mg/kg, however, pizotifen po- 
tentiated the deleterious effect of scopolamine, but 
this potentiation was not verified at higher doses 
and, therefore, it seems difficult to consider it as a 
consistent effect. 
Using a radial arm maze test (working memory 
protocol), Miura et al/44 reported that FG-7080, a 
novel serotonin re-uptake inhibitor (3 mg/kg, p.o.), 
attenuated the deleterious effects of scopolamine 
(0.25 mg/kg, s.c.). Also, FG-7080 administered be- 
fore an acquisition trial was able to attenuate the 
scopolamine-induced deficit in acquisition of a 
passive-avoidance response. 
3.3.1.3. Other approaches. An interesting study 
has been reported by Pavone et al. t69 Using a one-trial 
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passive-avoidance test, these authors have investi- 
gated the mnemonic effects of a post-trial adminis- 
tration of oxotremorine (a muscarinic agonist: 
0.0054).04 mg/kg, i.p.), 5-MeO-DMT (a non-specific 
serotonergic agonist: 0.5 2mg/kg, i.p.) or both 
drugs given together in two strains of mice showing 
a different sensitivity to cholinergic stimulation 
(DBA/2 and C57BL/6 mice). Oxotremorine improved 
retention performance, whereas 5-MeO-DMT im- 
paired it in both strains. In addition, 5-MeO-DMT 
was able to inhibit the oxotremorine-induced im- 
provement of performance. Altman et al. 4 reported 
that alaproclate, a serotonin uptake inhibitor, was 
able to potentiate the facilitatory effects of ox- 
otremorine on passive-avoidance performance. In an 
earlier experiment, Wallis et al. 247 have compared the 
behavioral effects of systemic treatment with the 
serotonergic antagonist cyproheptadine (1 and 
5 mg/kg, s.c.) and the serotonergic agonist (mCPP, 1 
and 3 mg, s.c.) in two lines of Spragu~Dawley rats 
differing in  their sensitivity to anticholinesterase 
treatment. Whilst cyproheptadine had no significant 
effect on water-rewarded operant responding, mCPP 
produced a dose-dependent decrease in responding. 
Interestingly, the latter effect was more pronounced 
in the line of rats showing the highest sensitivity to 
anticholinesterase treatment, a finding suggesting 
that the cholinergic and the serotonergic systems may 
interact in regulating some behavioral functions and 
that the level of regulations may, in some respects, be 
dependent upon genetically controlled factors. 
3.3.1.4. Conclusions. The experiments ummar- 
ized in this section indicate that a serotonergic de- 
pletion may decrease the efficacy of pharmacological 
agents enhancing cholinergic neurotransmission in 
reversing the cognitive consequences of systemic 
cholinergic blockade. They also suggest hat a sero- 
tonergic depletion may exacerbate the sensitivity 
of animals towards the cognitive consequences of 
anticholinergic drugs given systemically. 
3.3.2. Selective pharmacological pproaches. Using 
selective pharmacological approaches, essentially 
three types of serotonergic receptors have been inves- 
tigated as being potentially involved in a serotonergic 
modulation of cognitive function sensitive to cholin- 
ergic depletions. These receptors are of the 5-HTIA, 
5-HT 2 and 5-HT3 types. The studies have been carried 
out most often on intact or serotonin-depleted rats, 
and only a few studies were performed on rats with 
lesions that disrupted one or the other component 
of the central cholinergic system. A few studies 
also considered other 5-HT receptors, such as, for 
instance, the 5-HT~B receptors. 
3.3.2.1. 5-Hydroxytryptamine~A receptors. Riekki- 
nen et al. 2°5 have investigated the effects on water- 
maze performance of 8-OH-DPAT (30 #g/kg, i.p.), 
a 5-HTIA receptor agonist, and mecamylamine 
(2.5 g/kg, i.p.), both these drugs being given either 
40 min before a training trial or immediately after a 
training trial in intact and serotonin-depleted rats 
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(pCPA). In intact rats, the combined injection of 
8-OH-DPAT and mecamylamine impaired only 
working memory performance when the injection was 
made before training (post-training injections had no 
effect). In pCPA-treated rats, the drug-induced im- 
pairment was more pronounced than in intact rats. 
However, it is noteworthy that none of these effects 
was observed in well trained rats. Lee et  al. ll7 have 
shown that when it is infused directly after training 
into the lateral septum, 8-OH-DPAT (5 #g) is able to 
impair memory retrieval in a passive-avoidance task, 
whereas the infusion of fluoxetine or zimelidine, two 
inhibitors of 5-HT re-uptake, has beneficial effects 
upon memory. Riekkinen ~95 has found that both in 
scopolamine-treated rats and in rats with lesions of 
the medial septum, an injection of 8-OH-DPAT 
aggravated the effects of the lesion- or drug-induced 
cholinergic dysfunction on acquisition (generally as- 
sessed with a protocol using a pretraining injection) 
and consolidation (post-training injection) of a pas- 
sive-avoidance r sponse. Using an operant delayed 
matching-to-position task in order to measure short- 
term working memory performance in rats, Cole 
et  al. 51 reported that 8-OH-DPAT and ipsapirone 
improved the matching accuracy at the respective 
doses of 0.1 mg/kg and 3 mg/kg (delay: 30 s). Con- 
versely, NAN 190, a 5-HT~A antagonist, impaired 
performance at the dose of 4mg/kg. Scopolamine 
(0.14mg/kg) induced a delay-dependent impair- 
ment which was dose-dependently attenuated (0.1 
and 0.3 mg/kg) or aggravated (1 mg/kg) by 8-OH- 
DPAT. NAN 190 only tended to potentiate the 
deficit resulting from scopolamine treatment. 
Altogether, these data indicate that the activation 
of central 5-HT~A receptors may exacerbate memory 
deficits due to drug-induced or lesion-induced cholin- 
ergic dysfunctions. The 5-HT~A receptors involved in 
these deleterious effects on memory are probably 
post-junctional ones, even though low doses of sys- 
temically-given agonists primarily activate somato- 
dentritic autoreceptors such as the ones described on 
the serotonergic cell bodies in the raphe. Also, there 
is some recent evidence showing that part of the 
deleterious effects of 8-OH-DPAT might be mediated 
by 5-HT~A receptors located in the CA1 region of the 
hippocampus 42 and that their activation alters spatial 
discrimination without affecting visual discrimination 
capabilities. 
3.3.2.2. 5-Hydroxytryptamine2 r ceptors. Sakurai 
and Wenk 2~3 trained rats in an operant chamber 
according to a continuous non-matching-to-sample 
non-spatial task and investigated the effects of scopo- 
lamine (0.1, 0.2 and 0.3mg/kg, i.p.), ketanserin 
(14 mg/kg, i.p.) methysergide (15 and 20 mg/kg, i.p.), 
as well as of scopolamine (0.2 mg/kg, i.p.) combined 
with methysergide (15 mg/kg, i.p.) treatments. 
Methysergide and ketanserin block 5-HT2 receptors. 
They found scopolamine to impair performance, 
whereas ketanserin and methysergide had no effect. 
When given together, scopolamine and methysergide 
induced a deficit that was larger than after only 
scopolamine treatment (although the difference was 
not significant). Using an approach consisting of 
infusing ketanserin (0.3 or 0.5 pg) or ritanserin (0.3 
and 0.6/~g), another 5-HT2 antagonist, into the lat- 
eral septum of rats immediately after training in a 
passive-avoidance task, Lee et  al. ~t7 found both treat- 
ments to have no effect on memory. In rats submitted 
to pCPA treatment, scopolamine (0.1 mg/kg) sur- 
prisingly produced a deficit that was smaller than in 
intact rats. This difference, nevertheless, was no 
longer observed at a dosage of 0.3 mg/kg. The 
authors interpret this paradoxical protective ffect of 
pCPA-induced lesions on the deleterious effects of 
scopolamine as subsequent to an attenuation of the 
acetylcholine release inhibition due to serotonin 
depletion. Riekkinen et  al. ~94 reported ata suggest- 
ing that 5-HT 2 receptors may also be involved in the 
cognitive effects of concurrent blockade of cholin- 
ergic and serotonergic mechanisms. These authors 
investigated the effects on water-maze performance 
of scopolamine (0.Smg/kg, i.p.), mecamylamine 
(10mg/kg, i.p.) and methysergide (2.5, 7.5 and 
20 mg/kg, i.p.) with the appropriate control injec- 
tions. They found that scopolamine and mecamy- 
lamine impaired water-maze performance. The 
combined scopolamine and methysergide (7.5 and 
20 mg/kg) treatments induced a deficit that was larger 
than after only scopolamine treatment. However, 
methysergide did not exacerbate the deficit in 
mecamylamine-treated rats. Using a passive-avoid- 
ance test in mice, Matsuno et  al. ~32 have shown that 
post-training administration of ritanserin (dose 
range: 2.5-40 mg/kg, s.c.) or mianserin (dose range: 
5 20mg/kg, s.c.) had no effect on the passive- 
avoidance retention deficit induced by scopolamine 
treatment (0.75mg/kg, i.p.). In another study, 
Riekkinen ~95 reports DOI, a 5-HT 2 agonist, to impair 
passive-avoidance a quisition (pre-training injection) 
and consolidation (post-training injection), the latter 
effect being prevented by ketanserin. However, the 
co-injection of DOI and a subthreshold ose of 
scopolamine had no effect. Normile and Altman j61 
have investigated the effects of ketanserin passive- 
avoidance retention performance of both intact and 
NBM lesioned rats. They have found the post- 
training administration f ketanserin (10 mg/kg, i.p.) 
to facilitate retention in intact rats, but not in le- 
sioned rats, even at a dose of 30 mg/kg. Using aged 
rats, Normile et  al. 16° investigated the effects on step- 
through latency in a passive-avoidance task of 
physostigmine (dose range: 0.01-10 #g/kg, i.p.), ke- 
tanserin (1 mg/kg, i.p.), or both treatments combined. 
The injections were made immediately after training. 
While physostigmine improved performance ata dose 
of at least 0.1/tg/kg, a hundredfold lower dose was 
sufficient to induce similar beneficial effects when 
ketanserin was co-injected. In aged rats, cognitive 
deficits have also been attributed to a combined loss of 
cholinergic and serotonergic functions (e.g., Ref. 192). 
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Altogether, these results seem to suggest hat the 
blockade of central 5-HT 2 receptors may have some 
beneficial cognitive ffects, whereas their activation 
may rather impair cognitive function. However, the 
possibility that these effects may be mediated, under 
some conditions and in specific tasks, by a serotoner- 
gically determined modification of central cholinergic 
function does not seem to be as well established for 
5-HT2 receptors as for 5-HTIA receptors (see con- 
clusions below). Additionally, in the studies using 
ketanserin, a substance that also has a nanomolar 
affinity for ~1 adrenergic receptors and HI his- 
taminergic receptors, it is impossible to completely 
exclude that the observed effects were mediated over 
nonserotonergic mechanisms. 
3.3.2.3. 5-Hydroxytryptamine 3 r ceptors. Bram- 
billa et al. 37 have examined the effects of DAU 
6215 (for general pharmacology, see Ref. 206), 
a selective 5-HT 3 antagonist on passive-avoidance 
performance in rats that were given scopolamine 
(0.75 mg/kg, i.p.). Scopolamine alone disrupted the 
acquisition of a one-trial step-through passive- 
avoidance response, an effect which was counter- 
balanced according to a bell-shaped ose-response 
curve by DAU 6215. Using another 5-HT 3 antagonist 
in mice, Chugh et al. 5° reported that systemic post- 
training (one-day delay) treatment with tropisetron 
(previously called ICS 205930; 1 100pg/kg, i.p.) is 
not only able to enhance the step through latencies in 
a passive-avoidance task, but also that, at the dose of 
10 pg/kg, it may attenuate the disruptive ffects of 
scopolamine (3 mg/kg, i.p.) on memory retrieval, 
Costall et al. 57 have summarized a series of exper- 
iments in which scopolamine-treated adult mice, 
adult mice with NBM lesions and aged mice which 
sustained neither lesions nor scopolamine injections, 
were tested for habituation i a black and white test 
box system and for working memory in a food- 
rewarded T-maze alternation task. In both tests, 
the scopolamine-treated, the lesioned and the aged 
mice showed comparable deficits. These deficits could 
be attenuated by ondansetron (10-100 ng/kg, i.p.), 
zacopride (10-100 ng/kg, i.p.) and tropisetron 
(10-1000ng/kg, i.p.), three 5-HT 3 antagonists. In 
adult scopolamine-treated mice tested for reference 
memory in a water-maze task, the three 5-HT 3 antag- 
onists were again able to reduce the scopolamine- 
induced eficit. Also in a water maze used to assess 
spatial reference memory in rats, Pitsikas et al. 175 have 
found DAU 6215 (10 and 30 #g/kg, i.p.) to attenuate 
a scopolamine-induced l arning deficit (0.2 mg/kg, 
s.c.), an effect which was also found by Pitsikas and 
Algeri174 when oxiracetam was associated with scopo- 
lamine treatment. Beneficial effects of 5-HT 3 antag- 
onists were also found in marmosets exposed to 
scopolamine. 11'41'67 However, 5-HT 3 antagonists were 
not always found to attenuate the deleterious conse- 
quences of cholinergic dysfunctions. For instance, 
using a five-choice serial reaction time task, Muir 
et al. 15° assessed visual attentional function in NBM- 
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lesioned rats that were exposed to several drug treat- 
ments including phsysotigmine, nicotine and 
ondansetron. These authors reported that the lesion- 
induced eficit could be attenuated by physostigmine 
and nicotine, but not by  ondansetron (0.3 and 
10 ng/kg). 
3.3.2.4. Other 5-hydroxytryptamine r ceptors. 
Noda et al. ~59 investigated the role of cholinergic 
mechanisms in the behavioral effects of a 5-HTIB 
agonist, RU-24969. They found RU-24969 (2 and 
5mg/kg, i.p.) to induce hyperlocomotion and to 
reduce spontaneous alternation in a T-maze, both 
effects being also observed after scopolamine treat- 
ment (0.5-2 mg/kg, i.p.) and being counterbalanced 
by propranolol (5-HTtA/5-HT1B agonist). The 
authors interpret the behavioral effects of RU-24969 
as consecutive to5-HT~B-induced inhibition of acetyl- 
choline release in brain regions crucial for mnesic 
processes. The 5-HT4 receptors (e.g., Ref. 24) have 
also been shown to modulate cholinergic function in 
the brain and to have electrophysiological effects 
which can be blocked by scopolamine ( .g., Ref. 25). 
However, to our knowledge, no study has been 
published so far on the cognitive ffects of either a 
selective activation (e.g., BIMU 1 and BIMU 8 are 
5-HT 4 agonists) or a selective blockade (e.g., SDZ 
205557, DAU 6215 and DAU 6285 are 5-HT4 antag- 
onists) of this receptor in animals with drug-induced 
or lesion-induced cholinergic depletions. 
3.4. Summary  and  conc lus ions  
The acute (systemic drug treatments), semichronic 
(pCA and pCPA) or chronic (5,7-DHT) disruption of 
the central serotonergic function is able to potentiate 
the cognitive ffects of a drug-induced or a lesion- 
induced central cholinergic dysfunctioning in, at 
least, the septohippocampal and the basalocortical 
systems (for summary, see Table 4). In most exper- 
iments, the serotonin depletion alone is not sufficient 
to produce deleterious effects on learning or memory 
processes. 
As regards the septohippocampal system, it was 
found that following a multitransmitter hippocampal 
denervation, combined cholinergic and serotonergic 
grafts produced a level of functional (cognitive) 
recovery that neither single graft was able to induce. 
All these data point to the conclusion that 
interactions between the central serotonergic and 
cholinergic systems are relevant o cognition. Con- 
current manipulations of both systems with drugs 
specific for given receptor subtypes allowed to setup 
a better characterization f the pharmacological sub- 
strates which may be involved in the cholin- 
ergic/serotonergic interactions. In rats with 
drug-induced cholinergic dysfunctions, the activation 
of 5-HTIA or 5-HT1B receptors as well as the inhi- 
bition of 5-HTa receptors was found to exacerbate he 
deficit due to central muscarinic blockade or to 
cholinergic lesions. 
Conversely, the blockade of 5-HT 3 receptors was 
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Table 4. Synthetic outline of the main cognitive ffects of concurrent manipulations of the serotonergic and cholinergic 
systems in the rat brain 
Cognitive deficit due to Deficit aggravated by a Deficit attenuated by Task  Ref 
Medial septal esions 5,7-DHT (i.c.v.) Intrahippocampal co-grafts of MWM ~55'~58 
raphe and septal cell suspensions 
Medial septal esions 5,7-DHT (i.c.v.) Intrahippocampal grafts of a MWM 186 
raphe cell suspension 
Medial septum lesions 8-OH-DPAT (syst.) PA 195 
Medial septum lesions pCPA (syst.) THA (syst.) PA,MWM 199 
Fimbri~fornix lesions Intrahippocampal co-grafts of MWM t°3 
raphe and septal cell suspensions 
Nucleus basalis lesions Dorsal raphe lesions MWM TM 
Nucleus basalis lesions pCPA (syst.) PA ~°° 
Nucleus basalis lesions pCA (syst.) b CDNMST 13° 
Nucleus basalis lesions Ondansetron (syst.) BWTB ~7 
Zacropide (syst.) 
Tropisetron (syst.) 
pCA treatment (syst.) THA and physostigmine PA E32 
(syst.) 
pCPA (syst.) Nicotine (syst.) PA 193 
+ mecamylamine (syst.) 
Mecamylamine (syst.) MWM 197 
8-OH-DPAT (syst.) pCPA (syst.) MWM 2°s 
+ meeamylamine (syst.) 
Scopolamine (syst.) 5,7-DHT (i.c.v.) Pilocarpine (syst.) MWM 2°3 
Scopolamine (syst.) pCPA (syst.) PA,MWM 236 
Scopolamine (syst.) pizotifen (syst.) ~ StP 239 
Scopolamine (syst.) FG-7080 (syst.) RAM,PA 144 
Scopolamine (syst.) 8~OH-DPAT (syst.) PA 195 
Scopolamine (syst.) 8-OH-DPAT (syst.) d 8-OH-DPAT (syst.) ~ ODMTPT 51 
Scopolamine (syst.) Methysergide (syst.) CNMTST m 
Scopolamine (syst.) Methysergide (syst.) MWM 194 
Scopolamine (syst.) DAU 6215 (syst.) PA 37 
Scopolamine (syst.) Tropisetron (syst.) PA 5° 
Scapolamine (syst.) Alaproclate (syst.) Pilocarpine (syst.) f MWM 196 
Scopolamine (syst.) Ondansetron (syst.) BWTB 57 
Zacropide (syst.) 
Tropisetron (syst.) 
Scopolamine (syst.) DAU 6215 (syst.) MWM 175 
Scopolamine (syst) Propranolol (syst.) SA 159 
+ RU-24969 (syst.) 
For doses and other technical details, see text. BWTB, black and white testbox; CDNMST, cued delayed non-matching-to 
sample task; CNMTST, continuous non-matching-to-sample task; MWM, Morris water-maze; ODMTPT, operant 
delayed matching-to-position task; PA, passive avoidance; SA, spontaneous alternation; StP, swim-to-platform task; 
syst., treatment administered systemically. 
aNeither of these treatments has perturbating effects upon cognition when used alone; %nly slows down recovery from 
nucleus basalis lesions; Conly at an intermediate dose of 5 mg/kg; dat the doses of 0.1 and 0.3 mg/kg; eat the dose of 
1 mg/kg; fpilocarpine reduced the deficit resulting from combined scopolamine and alaproclate treatments. 
found to attenuate the cognitive deficits due to central 
cholinergic disruption. 
In vivo and in vitro, 5-HTIB agonists attenuate the 
release of acetylcholine in at least the hippocampus 
(see sections 2.4.1. and 2.4.2.). Thus, the cognitive 
perturbations induced by such agonists might, in 
some respects, be explained by their inhibitory effects 
on central cholinergic function. In vivo, a systemic 
administration of 5-HT~A or 5-HT3 agonists exerts 
facilitatory effects on acetylcholine release in the 
hippocampus, but neither of these agonists is able to 
enhance cognitive function in pharmacological or 
surgical paradigms of cholinergic dysfunction. Also 
5-HT 2 antagonists have facilitatory effects towards 
acetylcholine release in the hippocampus but, in 
acetylcholine-depleted animals, a systemic adminis- 
tration of such antagonists worsens the cognitive 
perturbations due to cholinergic depletion. All these 
findings appear to contradict he predictions that the 
in vitro and/or in vivo pharmacological experiments 
would lead us to make: a substance having facilita- 
tory effects on acetylcholine release should also en- 
hance cognitive functions. Thus, as regards the 
cognitive alterations which, in acetylcholine-depleted 
animals, are induced by agonists of 5-HTIA or 5-HT 3 
receptors, or antagonists of 5-HT 2 receptors, it seems 
justified to consider that the drug-induced cognitive 
alterations cannot be reduced to a simple and direct 
modulatory influence that the drugs might exert on 
central cholinergic function. These apparent contra- 
dictions between the expectations founded on in vivo 
and in vitro pharmacological approaches and the 
behavioral observations from psychopharmacologi- 
cal experiments strongly suggest hat the interaction 
between serotonergic and cholinergic systems in the 
brain is very complicate. In addition to the effects of 
Serotonergic modulation 
serotonin on cholinergic function, one has to consider 
the possibility that serotonin has its own cognitive 
actions, for instance in modulating functions that 
may be essential for mnesic processes to occur 
efficiently (e.g., anxiety, arousal, attention; for a 
review, see Ref. 224). 
Finally, we feel it necessary to particularly stress 
the importance of more methodological spects. In 
the experiments which used serotonin-depleted ani- 
mals exposed to cholinergic blockade in order to 
investigate the effects of additional drug treatments 
(nicotinic and muscarinic agonists or antagonist and 
drugs selective for different 5-HT receptor subtypes), 
there is a point which needs to be emphasized and 
which also applies to some experiments summarized 
in Section 3.1. In the studies using scopolamine asthe 
agent impairing task performance, the doses ranged 
from 0.2 to 5 mg/kg. This large range might account 
for some inconsistencies in the ability of other drugs 
to reverse or to potentiate the deleterious effects of 
scopolamine on cognition. One possibility is that 
when scopolamine is used at a dose inducing submax- 
imal cognitive impairments, concomitant manipula- 
tions of the serotonergic system may exacerbate or 
attenuate a cognitive perturbation. Conversely, when 
scopolamine is used at doses producing maximal 
disturbances (e.g., 5 mg/kg), there is no possibility to 
further exacerbate the deficit by other drugs and the 
possibility of observing drug-reversal effects might be 
smaller than in the case of doses inducing submaxi- 
mal effects. Another point is that in the studies using 
scopolamine, the scopolamine-induced ffects on 
cognition were interpreted as resulting directly from 
cholinergic blockade. Thus, as scopolamine-induced 
deficits may be reversed or attenuated by a number 
of non-cholinergic agents (e.g., Ref. 64) it may also 
be questioned whether the cognitive ffects of concur- 
rent cholinergic and serotonergic manipulations do 
not reflect alterations of other neurotransmitter sys- 
tems. Future experiments should help to resolve these 
problems, as well as others related to the role of 
serotonergic/cholinergic interactions in cognition. 
Since a large majority of the aforementioned studies 
have used the passive avoidance or the water-maze 
tasks to evaluate the mnesic impact of concurrent 
serotonergic and cholinergic dysfunctions, additional 
information should be gained from experiments u ing 
other mnesic tasks. Also, most experiments have been 
carried out to investigate he cognitive ffects of one 
specific agonist or antagonist in animals with pertur- 
bations of central cholinergic function induced by 
anticholinergic drug treatments or by lesions. A more 
systematic exploration might be based on protocols 
which would not only consider the effects of either an 
agonist or an antagonist of serotonin receptors, but 
also compare the effects of both types of treatments 
in the same animals or pay attention to serotonergic 
receptors which have not yet been taken into account 
(e.g., 5-HT4). Another crucial point that clearly de- 
serves further investigations is the identification of 
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the brain locus or system (the neuroanatomical sub- 
strate) in which the functional effects of a serotoner- 
gic/cholinergic interaction are determined. Regarding 
the latter point, lesion approaches combined to sys- 
temic drug injections, or even local intracerebral drug 
infusion techniques, represent, in addition to molecu- 
lar biology approaches, two possibilities that should 
allow further progress in the near future. It might also 
be helpful to direct experiments at determining the 
neurotransmitters involved in the different 'relays' of 
the polysynaptic loops in which a modification of the 
serotonergic nput may modify the activity of the 
cholinergic system. Finally, additional experiments 
should also try to better characterize the type of 
mnesic process that is sensitive to concurrent sero- 
tonergic/cholinergic manipulations. Do such manipu- 
lations alter the ability of the animals to pick up 
information ecessary to solve the task in their 
environment (by changing, for instance, the sig- 
nal/noise ratio), do they perturbate the consolidation 
processes (of either or both the target stimulus or 
the context), do they disturb the retrieval of ac- 
quired information or do they impair the ability to 
appropriately use the mnesic trace? 
4. GENERAL CONCLUSIONS 
The present review has tried to set up an outline of 
histological, electrophysiological, pharmacological 
and behavioral data suggesting that serotonin is able 
to modulate central cholinergic function and that this 
modulation may have, in some respects, cognitive 
implications, particularly as regards learning and 
memory processes. 
To conclude with some caution, a few additional 
qualifying remarks are necessary. In vitro findings 
show that an application of serotonin as well as that 
of 5-HT agonists or antagonists o stimulated slices 
from given brain regions may alter the evoked release 
of acetylcholine. However, these findings do not 
necessarily demonstrate hat the serotonergic modu- 
lation is directly occurring on the cholinergic terminal 
by means of 5-HT heteroceptors. During an electri- 
cally evoked or a potassium-evoked stimulation, all 
terminals present in the experimental material are 
stimulated and release part of their neurotransmitter 
content. Therefore, it cannot be excluded that a 
serotonin-induced attenuation of acetylcholine re- 
lease is mediated by a decreased or an increased 
release of another transmitter (different from sero- 
tonin) to which cholinergic terminals would be sensi- 
tive without being sensitive to 5-HT. This problem, 
however, can be circumvented in preparations using 
synaptosomes. In vivo, the problem gets even more 
complicated as the serotonergic nfluence on cholin- 
ergic function, especially when drug treatments are 
administered systemically, may involve complex 
polysynaptic loops, several brain regions and various 
neurotransmitter systems. Thus, although achange in 
the serotonergic input may result in a modification of 
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the cholinergic output, the number of intermediate 
events and their neurochemical identity are almost 
always unknown. Here, lesion techniques may be 
useful tools to explore the structural organization and 
the functional substrates ofsuch loops. Finally, at the 
most integrated level of organization, amely that of 
the organism, the degree of complexity reaches a 
maximum. At this level, the functional consequences 
of an interaction do not necessarily suppose two 
neurotransmitter systems to cooperate or interact 
directly (e.g., serotonin activating heteroceptors of
the cholinergic terminal). The functional conse- 
quences may also be determined by the cooperation 
between various functions working in parallel, each 
of which being considered as resulting from inter- 
actions involving various transmitter systems in the 
brain. Actually, that serotonin may modulate cogni- 
tive functions by a more or less direct influence on 
cholinergic mechanisms in the brain is a concept hat 
has a heuristic value equivalent to considering that 
serotonin produces a functional change at the level of 
the organism (e.g., on attentional processes, on 
motricity, or on arousal) that, in turn, would allow an 
enhanced efficiency of the cholinergic contribution to
another function of the organism (e.g., learning). 
In any case, the literature contains a series of 
experimental rguments finding their roots in histo- 
logical, electrophysiological, pharmacological nd 
behavioral research fields and demonstrating or 
suggesting that, in the mammalian brain, cholinergic 
function may be under serotonergic modulatory 
influence and that this modulation may have cogni- 
tive implications. However, these arguments should 
not be regarded as an invitation to share the idea that 
cognitive processes which involve cholinergic func- 
tion may be simply explained by additional consider- 
ation of serotonergic modulatory mechanisms. 
Indeed, while the purpose of this review was to 
provide an overview of the serotonergic modulation 
of cholinergic and cognitive functions, it must be 
emphasized that interactions involving neurotrans- 
mitter systems other than the serotonergic one have 
also been dealt with in neuroscience. Each of these 
interactions is nowadays sufficiently documented 
and might become the subject of reviews. To 
briefly mention a few of them, research during the 
last twenty years has demonstrated the cogni- 
tive relevance of cholinergic/noradrenergic inter- 
actions, 61'62'63'64'85'98'2°2'2°4'212 cholinergic/glutamatergic 
interactions, 98 GABAergic/cholinergic ones 215 and 
other ones involving dopamine, ~2° opiates 
(endorphins, enkephalins) or substance p.64 
Also, as regards the topic of this review, we have 
deliberately chosen to concentrate xclusively on 
one side of the cholinergic/serotonergic interaction, 
namely that serotonin may modulate cholinergic 
processes in the brain. There is another viewpoint 
in which acetylcholine is considered as a neurotrans- 
mitter that may modulate serotonergic processes. 
Although this aspect is less well documented than the 
serotonergic modulation of cholinergic function, 
there are some recent findings uggesting that, under 
some conditions, a modification of cholinergic func- 
tion in the brain may have important consequential 
effects upon serotonergic function (e.g., Refs 19, 184). 
Finally, another aspect hat was not considered in 
this review, especially as concerns the interpretation 
of the concurrent serotonergic/cholinergic lesion- 
induced ysfunctions followed by systemic treatment 
with serotonergic drugs, is that serotonin may exert 
neurotrophic effects on cholinergic neurons mediated 
by at least 5-HTIA receptors (e.g., Refs 183, 254). 
Thus, the possibility arises that the cognitive ffects 
attributed to acute drug-induced functional changes 
also involve structural modifications induced by neu- 
rotrophic effects of serotonergic drugs, an interpret- 
ation that might apply to the observation reported by 
Markowska and Wenk 13° in rats with lesions of the 
NBM (see Section 3.1.2.). 
In his introduction to the book edited by Levin, 
Decker and Butcher, H9 Russell quotes the following 
sentences written by Moore and Mahler in their 
'Introduction to Molecular Psychology': ~45 "We are 
today close to a critical point in history at which the 
mind of man by taking thought (and making exper- 
iments) will be able to understand the chemical and 
physical mechanisms responsible for thought itself. Just 
as molecular biology has provided a chemical basis for 
heredity and evolution, molecular psychology will elu- 
cidate the chemistry of memory, learning, sensation, 
emotion and finally human consciousness". It is tempt- 
ing to add that 30 years later, we are merely coming 
closer to this critical point without finding a way to 
reach it. We approach it like an asymptotic function 
approaches a straight line. Nevertheless, along this 
path, new (yet experimental) horizons have been 
opened in terms of treating cognitive correlates of a 
neurodegenerative disease such as AD. Evidence has 
emerged suggesting that, in patients with AD, the 
symptomatic treatment of cognitive dysfunctions 
should orient towards pharmacological tools recog- 
nizing that the disease is a multitransmitter system 
disease, and not a disease that mainly affects the 
forebrain cholinergic system (e.g., Refs 5, 13, 79, 86, 
89, 129, 168). In that concern, one should question 
whether paradigms of selective cholinergic lesions 
(e.g., Refs 17, 30, 87, 157) are really more appropriate 
animal models of AD than lesion or pharmacological 
paradigms producing simultaneous alterations in sev- 
eral neurotransmitter systems. Several authors have 
considered such an approach. Beside Ingram et al. 93 
who addressed the therapeutical value of combined 
glutamatergic (N-methyl-D-aspartate ype) and 
cholinergic treatments, of more relevance to the 
present review is the idea raised by Bowen's group 33'74 
regarding the multiple neurotransmitter deficits 
found in the cortex of patients with AD, the possible 
cognitive implications of these deficits and the novel 
therapeutical perspectives which ensue therefrom. 
The authors reviewed a series of arguments 
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suggesting that in the cortex of AD patients, one 
major  chemoanatomical  change beside the cholin- 
ergic depletion is the degeneration of cortical 
glutamatergic, presumably pyramidal, neurons. Con- 
versely, the cortical serotonergic innervat ion seems 
to be relatively preserved. Furthermore,  when ob- 
served, the loss of serotonergic terminals can be 
compensated for by surviving terminals which in- 
crease the 5-HT turnover. It is known that cortical 
pyramidal neurons are under a hyperpolarizing influ- 
ence of serotonin that probably involves 5-HTIA 
receptors. The degeneration of these pyramidal neur- 
ons may result in a reduced excitatory glutamatergic 
cortical input, a reduction which may account for 
cognitive alterations as can be extrapolated from 
animal studies (e.g., Ref. 93). The glutamatergic 
cortical tone may be further reduced subsequently to
the degeneration of the basalocortical neurons exert- 
ing an excitatory cholinergic modulat ion,  whilst the 
inhibitory tone exerted by the preserved GABAergic 
neurons is maintained. Therefore, Francis et al. TM 
have proposed to consider the use of drugs that 
would reduce the serotonergic tone (e.g., 5-HTIA 
or 5-HT 3 antagonists) as an interesting perspective 
of transmitter-based therapies for the cognitive defi- 
ciencies in sufferers of AD. 
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